KOL | Hiroshi FujishimaDepartment of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, fujishima117@gmail.com | Department of Ophthalmology, Keio University ... |
Kol melanjutkan untuk Hiroshi Fujishima
| Year | |
|---|---|
| 2021 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa 230-0063, Japan;, Ophthalmology, Tsurumi University Dental Hospital, Yokohama, Kanagawa, Japan |
| 2020 | Department of Ophthalmology, Keio University School of Medicine, Tokyo 160-0016, Japan;, (E.S.);, (N.A.);, (Y.O.) Fujishima Eye Clinic, Niigata 949-6600, Japan |
| 2019 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Tsurumi-ku 230-8501, Kanagawa, Japan;, (N.K.);, (A.S.);, (H.F.) Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2016 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan |
| 2015 | From the *Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa; and †Department of Ophthalmology, Tokyo Saiseikai Central Hospital; and ‡J&J Ocular Surface and Visual Optics Department, Keio University School of Medicine, Tokyo, Japan. |
| 2014 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Yokohama, Japan |
| 2012 | Department of Ophthalmology, Tsurumi University School of Dental Medicine, Kanagawa |
| 2011 | Department of Ophthalmology, Tsurumi University Dental Hospital, Kanagawa, Japan. |
| 2010 | Department of Ophthalmology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan. |
| 2009 | Department of Ophthalmology, Keio University, Tokyo, Japan. |
| 2008 | Department of Ophthalmology, International University of Welfare, Mita Hospital, Tokyo, Japan |
| 2007 | International University of Health and Welfare, Department of Ophthalmology, Mita Hospital, 1-4-3 Mita, Minato-ku, Tokyo 108-8329, Japan. |
| 2006 | From the *Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan; †Keio University School of Medicine, Tokyo, Japan; and ‡Hara Eye Clinic, Otawara, Tochigi Prefecture, Japan. Department of Ophthalmology, Keio University School of Medicine |
| 2005 | From the Department of Ophthalmology, Keio University, Tokyo, Japan; the Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13, Ichikawa, Chiba 272-8513, Japan |
| 2004 | From the Departments of *Ophthalmology and †Dermatology, Tokyo Dental College, Ichikawa, Chiba, Japan. Department of Ophthalmology, Keio University, Tokyo, Japan |
| 2003 | Department of Ophthalmology, Tokyo Dental College, Chiba, Japan |
| 2002 | Department of Ophthalmology, Tokyo Dental College, Sugano, Ichikawa, Japan. |
| 2001 | From the Departments of Ophthalmology (N.A-K., K.F., K.T., K.U., H.F.) and Dermatology (S.T.), Tokyo Dental College, Chiba, Japan. |
| 1998 | Department of Ophthalmology, Tokyo Dental College, Ichikawa, Chiba, Japan. |
| 1997 | Department of Ophthalmology, Tokyo Dental College, Chiba |
| 1996 | Department of Ophthalmology, Tokyo Dental College; Department of Ophthalmology, Keio University School of Medicine |
| 1995 | Chiba, Tokyo, and Akita, Japan Department of Ophthalmology Tokyo Dental College, Chiba |
| 1994 | Department of Ophthalmology, School of Medicine, Keio University, Tokyo, Japan. |
Hiroshi Fujishima: Statistik pengaruh
Jalankan laporan
| Concept | World rank |
|---|---|
| commercial eyewash solutions | #1 |
| allergens levocabastine | #1 |
| allerwatch positivity rate | #1 |
| subjective ocular symptoms | #1 |
| patients allergic conjunctivitis | #1 |
| suspension treating | #1 |
| radioimmunoassay il4 | #1 |
| 01 tacrolimus eye | #1 |
| efficacy bromfenac sodium | #1 |
| akc treatment | #1 |
| postoperative conjunctivitis | #1 |
| stat6results | #1 |
| inhibition eotaxin1 | #1 |
| eye allerwatch | #1 |
| akc | #1 |
| efficacy fml | #1 |
| tacrolimus ophthalmic suspension | #1 |
| cytokinestimulation pharmacologic intervention | #1 |
| fluorometholone 002 | #1 |
| initiation tacrolimus treatment | #1 |
| eye itching | #1 |
| allergic postoperative | #1 |
| sodium bf | #1 |
| vkc april | #1 |
| accuracy conjunctivitis | #1 |
| drops elicited | #1 |
| 10 objective signs | #1 |
| experience 01 | #1 |
| bromfenac sodium bf | #1 |
| patients capilia | #1 |
| allerwatch higher | #1 |
| hundredandseventy eyes | #1 |
| scores hyperemia | #1 |
| commercial eyewash | #1 |
| dha western blotting | #1 |
| cases severe conjunctivitis | #1 |
| levocabastine artificial | #1 |
| adeno eye | #1 |
| tacrolimus eye drop | #1 |
| pge2 human conjunctival | #1 |
| conjunctivitis concomitantly | #1 |
| capilia adeno | #1 |
| atopic keratoconjunctivitis akc | #1 |
| epithelial pge2 | #1 |
| exacerbation vkc | #1 |
| objective findings conclusions | #1 |
| immunocytochemical study rtpcr | #1 |
| production ketotifen fumarate | #1 |
| hyperemia pain | #1 |
| levocabastine artificial tears | #1 |
| tacrolimus ophthalmic solution | #1 |
| conjunctivitis helper | #1 |
| tacrolimus tears | #1 |
| 12 patients akc | #1 |
| nsaids systemic control | #1 |
| vkc cases | #1 |
| fml patients | #1 |
| keratoconjunctivitis vernal | #1 |
| primary human conjunctival | #1 |
| adenovirus capilia | #1 |
| child conjunctivitis | #1 |
| capilia adeno eye | #1 |
| eye surface years | #1 |
| eyebon eye | #1 |
| drop levocabastine | #1 |
| dscg fml | #1 |
| solution allergic | #1 |
| tnfalpha tranilast dexamethasone | #1 |
| akc methods | #1 |
| keratoconjunctivitis male | #1 |
| conjunctivitis aims | #1 |
| fml administered | #1 |
| concomitant bf | #1 |
| eyewash solution | #1 |
| 3 months signs | #1 |
| tranilast dexamethasone | #1 |
| akc allergic | #1 |
| instillation bromfenac | #1 |
| characterized conjunctival | #1 |
| diagnostic accuracy conjunctivitis | #1 |
| tacrolimus eye | #1 |
| compared fluorometholone | #1 |
| eyebon | #1 |
| ige allerwatch | #1 |
| allergic conjunctivitis efficacy | #1 |
| conclusions objective assessments | #1 |
| tranilast production | #1 |
| fml dscg | #1 |
| allerwatch diagnostic accuracy | #1 |
| prostaglandin tears | #1 |
| pcr eotaxin1 | #1 |
| eotaxin1 production | #1 |
| allergic tranilast | #1 |
| eyewash | #1 |
| test capilia | #1 |
| rate allerwatch | #1 |
| tacrolimus eye treatment | #1 |
| tranilast eotaxin1 | #1 |
| keratoconjunctivitis akc | #1 |
| bak epithelium disorders | #1 |
| cox2 conjunctival | #1 |
| akc patients | #1 |
| akc vkc | #1 |
| tacrolimus eye drops | #1 |
| fourgraded severity | #1 |
| allergic corneal | #1 |
| solution ocular | #1 |
| dscg symptoms | #1 |
| bromfenac sodium | #1 |
| severity objective signs | #1 |
| akc administration | #1 |
| il4 tranilast | #1 |
| allergenmediated conjunctivitis | #1 |
| include conjunctival | #1 |
| action child conjunctivitis | #1 |
| allergic docosahexaenoic | #1 |
| allergic enzyme | #1 |
| ocular allergic diseases | #1 |
| conjunctival fibroblasts production | #1 |
| allergic conjunctivitis drop | #1 |
| talymus | #1 |
| conjunctivitis including | #1 |
| systemic control pain | #1 |
| conjunctivitis seasonal | #1 |
| eyewash solutions bak | #1 |
| dscg 005 | #1 |
| higher akc | #1 |
| allerwatch tests | #1 |
| adult cedrus conjunctivitis | #1 |
| adverse events scores | #1 |
| artificial tears positive | #1 |
| positivity rate allerwatch | #1 |
| tacrolimus ophthalmic | #1 |
| instillation symptoms | #1 |
| initiating tacrolimus | #1 |
| incubated interleukin | #1 |
| patients severe conjunctivitis | #1 |
| production conjunctival fibroblasts | #1 |
| tears allergic patients | #1 |
| binocular conjunctivitis | #1 |
| il4 tear | #1 |
| keratoconjunctivitis background | #1 |
| conjunctivitis conjunctival | #1 |
| higher capilia | #1 |
| conjunctival cedar | #1 |
| corneal epithelium disorders | #1 |
| allergic conjunctivitis | #1 |
| signs palpebral | #1 |
| vkc conclusions | #1 |
| keratocytes tnfα | #1 |
| fumarate dexamethasone | #1 |
| bf concomitantly | #1 |
| samples allergic conjunctivitis | #1 |
| itchy sensation | #1 |
| conjunctivitis scleritis episcleritis | #1 |
| tears conjunctival fibroblasts | #1 |
| 01 ophthalmic solution | #1 |
| washing allergens | #1 |
| satisfaction suspensions | #1 |
| bak epithelium | #1 |
| akc compared | #1 |
| diseases tear | #1 |
| ketotifen fumarate dexamethasone | #1 |
| conjunctival fibroblasts | #1 |
| il4 causing | #1 |
| cd3 cd4bearing cells | #1 |
| tears allergic | #1 |
| itching levocabastine | #1 |
| 0001 allerwatch | #1 |
| severe binocular conjunctivitis | #1 |
| improvement combinedtreatment | #1 |
| fml 002 | #1 |
| commercial washing solution | #1 |
| vkc akc | #1 |
| bromobenzenes conjunctivitis | #1 |
| antagonists child conjunctivitis | #1 |
| bf fml | #1 |
| rapid ophthalmic | #1 |
| dscg bf | #1 |
| clinical signs akc | #1 |
| epithelium disorders | #1 |
| severe akc | #1 |
| selective chemotactic effects | #1 |
| akc tear | #1 |
| rsv conjunctival | #1 |
| atopic keratoconjunctivitis | #1 |
| severe conjunctivitis eyes | #1 |
| eye wash | #1 |
| eotaxin conjunctival fibroblasts | #1 |
| sodium ophthalmic solution | #1 |
| akc vernal | #1 |
| release inhibitor purpose | #1 |
| eyewash solutions | #1 |
| cedrus conjunctivitis | #1 |
| suppressing pge2 production | #1 |
| eyewash solution bak | #1 |
| treatment vernal keratoconjunctivitis | #1 |
| selected fml | #1 |
| therapy levocabastine | #1 |
| patients akc | #1 |
| production tranilast | #1 |
| conjunctivitis japanese | #1 |
| scleritis tacrolimus | #1 |
| conjunctivitis treated | #1 |
| patients atopic keratoconjunctivitis | #1 |
| bromfenac sodium treatment | #1 |
| iop akc | #1 |
| ded anti | #1 |
| sodium allergic | #1 |
| dha il4 | #1 |
| conjunctivitis enrolled | #1 |
| eye fml | #1 |
| corneal damage patients | #2 |
| largescale study protocol | #2 |
| corneal temperature patients | #2 |
| cac test | #2 |
| 1 month tacrolimus | #2 |
| sem575 | #2 |
| drops conjunctival | #2 |
| adjustments epitheliopathy score | #2 |
| simple resection regrowth | #2 |
| drops refractory | #2 |
| nonpreserved eyewash solution | #2 |
| edema height | #2 |
| swelling folliculosis | #2 |
| efficacy severe akc | #2 |
| signs blood concentration | #2 |
| olopatadine ocular | #2 |
| including akc | #2 |
| elasticity severity | #2 |
| excision cobblestonelike papillae | #2 |
| papillae mucous discharge | #2 |
| papillary formation | #2 |
| akc aureus | #2 |
| severe allergic conjunctivitis | #2 |
| patients corneal ulcers | #2 |
| superiority epinastine | #2 |
| conjunctivitis condition | #2 |
| eyelid atopic dermatitis | #2 |
| correlation eosinophils | #2 |
| epinastine ophthalmic solution | #2 |
| noninferiority olopatadine | #2 |
| brush cytology samples | #2 |
| adjuvant fluorometholone 95 | #2 |
| objective signs baseline | #2 |
| papilla accompanied | #2 |
| elasticity eyelid | #2 |
| talymus akc | #2 |
| olopatadine cedar | #2 |
| recurrence corneal complications | #2 |
| suspension talymus | #2 |
| drop steroid | #2 |
| betamethasone glaucoma | #2 |
| unpaired ttest talymus | #2 |
| plaques 791 | #2 |
| ecp severity markers | #2 |
| akc levels | #2 |
| akc sac patients | #2 |
| giant papillae formation | #2 |
| diagnosis ensured | #2 |
| control subjects eyes | #2 |
| sodium bromfenac | #2 |
| refractory allergic | #2 |
| regrowth papillae | #2 |
| corneal complications height | #2 |
| deqs tear | #2 |
| folliculosis papillae | #2 |
| ari ocular | #2 |
| tacrolimus 12 weeks | #2 |
| corneal epitheliopathy score | #2 |
| 001 brush | #2 |
| period rhodanine | #2 |
| bromfenac ophthalmic solution | #2 |
| improvement vital staining | #2 |
| corneal epithelial signs | #2 |
| score topical | #2 |
| epinastine 15 minutes | #2 |
| eyelid atopic | #2 |
| inflammatory child child | #2 |
| based papillae | #2 |
| topical tacrolimus combination | #2 |
| akc young adult | #2 |
| oral aldose | #2 |
| baseline papillae | #2 |
| severity corneal complications | #2 |
| proliferative called | #2 |
| premedication combined | #2 |
| tacrolimus detection | #2 |
| detected akc | #2 |
| severity corneal damage | #2 |
| representative subjective | #2 |
| ensured proving | #2 |
| epitheliopathy steroids | #2 |
| akc 6 | #2 |
| patients tacrolimus eye | #2 |
| scores papillary | #2 |
| tacrolimus topical | #2 |
| akc allergic diagnosis | #2 |
| accompanied subjective | #2 |
| steroid metaregression | #2 |
| bromfenac sodium bromfenac | #2 |
| allergic diagnosis | #2 |
| tear ige correlation | #2 |
| resolution thermography | #2 |
| production specular | #2 |
| lid skin | #2 |
| blepharitis ceramides | #2 |
| ulcer complain | #2 |
| shield ulcers patients | #2 |
| ketotifen dexamethasone | #2 |
| regrowth 7 eyes | #2 |
| test papillae | #2 |
| adjuvant fluorometholone | #2 |
| treatment atopic blepharitis | #2 |
| month eyewash | #2 |
| papillae severe | #2 |
| japan akc | #2 |
| tacrolimus detection limit | #2 |
| allergic conjunctivitis akc | #2 |
| pge2 tears | #2 |
| epitheliopathy refractory | #2 |
| effects topical tacrolimus | #2 |
| keratoconjunctivitis corneal | #2 |
| akc 10 | #2 |
| eyes betamethasone | #2 |
| eyes 824 | #2 |
| total clinical signs | #2 |
| papillary excision | #2 |
| correlation neutrophils | #2 |
| conjunctivitis proliferative | #2 |
| recurrence corneal lesions | #2 |
| selected bf | #2 |
| formation palpebral | #2 |
| prevalence akc | #2 |
| rhodanine rose | #2 |
| cedrus conjunctiva | #2 |
| tacrolimus 1 month | #2 |
| mucous discharge severity | #2 |
| disease antiallergic | #2 |
| tacrolimus iop | #2 |
| cobblestonelike papillae | #2 |
| placebo noninferiority | #2 |
| allergic conjunctivitis ige | #2 |
| allergy accompanied | #2 |
| oral ari administration | #2 |
| japan topical tacrolimus | #2 |
| patients severe akc | #2 |
| correlation fluorescein | #2 |
| methods thirtysix patients | #2 |
| tarsal brush | #2 |
| edema corneal damage | #2 |
| formation akc | #2 |
| solution epinastine | #2 |
| adjustments epitheliopathy | #2 |
| vkc atopic keratoconjunctivitis | #2 |
| topical antiallergic agents | #2 |
| tears thiazolidines | #2 |
| giant papillary formation | #2 |
| conjunctiva atopic | #2 |
| score adjustments | #2 |
| tear film layer | #2 |
| papillae akc | #2 |
| epitheliopathy shield | #2 |
| conjunctivitis adolescent | #2 |
| hyperemia lacrimation | #2 |
| female humans akc | #2 |
| atopic diagnostic techniques | #2 |
| limbal swelling | #2 |
| mmc 7 eyes | #2 |
| elevation tacrolimus | #2 |
| corneal findings | #2 |
| brush cytology patients | #2 |
| drops hyperemia | #2 |
| tacrolimus tonometry | #2 |
| solutions japan | #2 |
| endpoint itching scale | #2 |
| conjunctival injection reduction | #2 |
| oral ari ono2235 | #2 |
| seasonal allergic conjunctivitis | #2 |
| papillae preventing | #2 |
| conjunctival injection edema | #2 |
| cytodiagnosis dermatitis | #2 |
| immunoregulatory effects study | #2 |
| 18 akc | #2 |
| olopatadine visit | #2 |
| papillae limbus | #2 |
| sac healthy | #2 |
| corneal lesions | #2 |
| cutometer sem575 | #2 |
| administered elf | #2 |
| drop concomitantly | #2 |
| severity eyelid | #2 |
| corneal recurrences | #2 |
| lacrimation objective | #2 |
| ecp levels akc | #2 |
| asthma heart diseases | #2 |
| treated bromfenac | #2 |
| adjuvant betamethasone | #2 |
| 95 adjuvant betamethasone | #2 |
| sem575 quantitatively | #2 |
| decrease corneal temperature | #2 |
| cornea grading | #2 |
| normal blinking patients | #2 |
| epinastine superiority | #2 |
| aided papillary | #2 |
| signs decreased | #2 |
| simple papillary resection | #2 |
| vkc japan | #2 |
| treatment tear | #2 |
| suspension lactoferrin | #2 |
| conjunctivitis representative | #2 |
| lesions allergic | #2 |
| akc adolescent | #2 |
| treatment shield ulcer | #2 |
| effects tacrolimus | #2 |
| allergic endophthalmitis | #2 |
| conjunctiva conjunctivitis allergic | #2 |
| allergic conjunctivitis levocabastine | #2 |
| akc 10 eyes | #2 |
| scores tacrolimus | #2 |
| lactoferrin 01 | #2 |
| bovine placebo | #2 |
| bromfenac effective | #2 |
| tacrolimus published data | #2 |
| conjunctival corneal cells | #2 |
| total signs symptoms | #2 |
| csa akc | #2 |
| conjunctivitis 10 | #2 |
| defined conjunctival | #2 |
| akc patients correlation | #2 |
| atopic blepharitis | #2 |
| complain foreign | #2 |
| neutrophils corneal damage | #2 |
| treatment total signs | #2 |
| sodium ophthalmic | #2 |
| neutrophils brush | #2 |
| patients shield | #2 |
| tacrolimus lessen | #2 |
| improvement corneal fluorescein | #2 |
| corneal ulcers patients | #2 |
| oral ari | #2 |
| study designopen cohort | #2 |
| conjunctivitis purpose | #2 |
| factor vkc | #2 |
| diabetic patients ono2235 | #2 |
| administration specular | #2 |
| conventional antiallergic drugs | #2 |
| akc 1 | #2 |
| conjunctiva bulbar | #2 |
| vkc 5 | #2 |
| severity corneal lesions | #2 |
| lower conjunctival sacs | #2 |
| skin elasticity patients | #2 |
| nonwash | #2 |
| air pollutants prevalence | #2 |
| epitheliopathy corneal | #2 |
| eyewash 005 | #2 |
| post cataract surgery | #2 |
| akc adult | #2 |
| dryness scores | #2 |
| fluorescein conjunctival injection | #2 |
| dermatitis remission | #2 |
| environmental studies prevalence | #2 |
| tacrolimus shield | #2 |
| iop topical steroids | #2 |
| muc16 immunohistochemistry | #2 |
| akc treated | #2 |
| conclusions bromfenac | #2 |
| serum allergic parameters | #2 |
| conjunctivitis retrospective | #2 |
| 2helper cell | #2 |
| pollutants prevalence | #2 |
| height papillae | #2 |
| benzophenones bromobenzenes | #2 |
| bovine entericcoated lactoferrin | #2 |
| reported eotaxin | #2 |
| eyelid elasticity | #2 |
| patients shield ulcers | #2 |
| aureussecreted enterotoxins | #2 |
| sem575 clinical | #2 |
| lessen steroid | #2 |
| administered elf bovine | #2 |
| conjunctivitis epitheliopathy | #2 |
| extents corneal | #2 |
| tears akc | #2 |
| keratoconjunctivitis age | #2 |
| steroids epitheliopathy | #2 |
| mmc aided | #2 |
| evaluate superiority | #2 |
| ceramide gel application | #2 |
| ocular surface mucin | #2 |
| conjunctival findings severity | #2 |
| epitheliopathy score | #2 |
| diathesis subjective | #2 |
| corneal damage height | #2 |
| treatment ecp concentrations | #2 |
| 062 tear | #2 |
| ophthalmic nsaid | #2 |
| epitheliopathy patients | #2 |
| mucin analyzed | #2 |
| corneal lesions regrowth | #2 |
| metaregression analysis glaucoma | #2 |
| excision cobblestone | #2 |
| eosinophils corneal damage | #2 |
| concomitantly abovementioned | #2 |
| eyelid skin elasticity | #2 |
| japan topical | #2 |
| corneal epitheliopathy | #2 |
| conjunctiva papillary | #2 |
| vkc relevant factor | #3 |
| uncontrollable glaucoma | #3 |
| akc alterations | #3 |
| formation vkc | #3 |
| corneal complications1 | #3 |
| drop selected | #3 |
| ulcers plaques | #3 |
| 5 eyes akc | #3 |
| akc confocal microscopy | #3 |
| signs remission | #3 |
| patients pilocarpine tablets | #3 |
| scored global | #3 |
| ocular surface diabetes | #3 |
| corneal akc | #3 |
| lamp device | #3 |
| scale tmh | #3 |
| oct graticule | #3 |
| aureus akc patients | #3 |
| cytology impression | #3 |
| uncontrollable glaucoma trabeculectomy | #3 |
| epithelium adverse | #3 |
| cooling cataract | #3 |
| icecold eye mask | #3 |
| superior keratoconjunctiva | #3 |
| allergic cornea | #3 |
| temperature evaluate | #3 |
| muc1 brush cytology | #3 |
| diclofenac epithelium | #3 |
| allerwatch | #3 |
| 5ac brush | #3 |
| akc persistent | #3 |
| keratoconjunctivitis leupeptins | #3 |
| july pm25 | #3 |
| healed amniotic | #3 |
| cells brush cytology | #3 |
| histamine superficial cells | #3 |
| tear periostin biomarker | #3 |
| patching case | #3 |
| eosinophils corneal | #3 |
| akc tear periostin | #3 |
| eyes allergic | #3 |
| papillae morphometric | #3 |
| 1 month initiation | #3 |
| operation eye | #3 |
| periostin comorbidities | #3 |
| alterations tear | #3 |
| conjunctivitis allergic | #3 |
| 5ac mrna | #3 |
| epinastine placebo | #3 |
| autumnal pollen | #3 |
| tmh measurement | #3 |
| tear periostin comorbidities | #3 |
| protein conjunctival fibroblasts | #3 |
| fibronectin normal controls | #3 |
| 12 akc patients | #3 |
| membrane uncontrollable | #3 |
| vkc differences | #3 |
| akc biomarkers | #3 |
| akc dyes humans | #3 |
| allergic corneal diseases | #3 |
| 005 ophthalmic solution | #3 |
| laser flarecellmetry | #3 |
| vkc eyes | #3 |
| immunosuppressive eye | #3 |
| papillae upper | #3 |
| pilocarpine visante | #3 |
| eyes akc | #3 |
| vkc sac | #3 |
| akc comorbidities | #3 |
| eye cooling | #3 |
| akc higher muc1 | #3 |
| 21 akc | #3 |
| allergic corneal ulcer | #3 |
| existence par2 | #3 |
| decline corneal | #3 |
| vivo corneal akc | #3 |
| superior limbic portion | #3 |
| conjunctivitis lymphocytes | #3 |
| healing dramatic healing | #3 |
| macroerosions | #3 |
| thermography evaluate | #3 |
| production conjunctival | #3 |
| underwent periodic | #3 |
| 22 eyes 100 | #3 |
| ssdry | #3 |
| treatment vernal | #3 |
| rtpcr par2 | #3 |
| severe allergic patients | #3 |
| superficial cells conjunctiva | #3 |
| formation vernal | #3 |
| 13 eyes 69 | #3 |
| fluorescein scale | #3 |
| histamine conjunctival cells | #3 |
| dry eye eye | #3 |
| lower muc5ac | #3 |
| evaluate tear | #3 |
| association outpatient attendance | #3 |
| treatment atopic keratoconjunctivitis | #3 |
| mmcaided papillary resection | #3 |
| solutions prospective | #3 |
| pollen postoperative | #3 |
| conjunctival fibroblasts tryptase | #3 |
| conjunctivitis negative | #3 |
| cell flare count | #3 |
| histamine specimens | #3 |
| drops treat | #3 |
| ulcer persistent | #3 |
| akc eyes | #3 |
| outpatient visits july | #3 |
| efficacy bromfenac | #3 |
| topical cyclosporine 01 | #3 |
| nuclei vkc | #3 |
| prospectively diclofenac | #3 |
| 005 mmc | #3 |
| reaction conjunctiva | #3 |
| ophthalmic solution placebo | #3 |
| conjunctivitis pm25 | #3 |
| interleukin4 tacrolimus | #3 |
| ebv ade | #3 |
| tissue remodeling exacerbation | #3 |
| conjunctiva allergic | #3 |
| ulcer akc | #3 |
| fibers lnfs | #3 |
| histamine cedar | #3 |
| improvement squamous metaplasia | #3 |
| child conjunctiva | #3 |
| prophylaxis conjunctival | #3 |
| keratoconjunctivitis vkc | #3 |
| akc serum periostin | #3 |
| measurements schirmer | #3 |
| hyperemia allergic | #3 |
| adedry eye | #3 |
| induced inflammation lenses | #3 |
| diseases acds | #3 |
| dramatic healing | #3 |
| treatment strip meniscometry | #3 |
| tryptase increases | #3 |
| 01 bromfenac | #3 |
| patients tmh measurements | #3 |
| cell metry | #3 |
| nbs normal eyes | #3 |
| glaucoma amniotic | #3 |
| central corneal temperature | #3 |
| sde controls | #3 |
| vkc levels | #3 |
| laser cellflaremetry | #3 |
| hydrochloride 01 | #3 |
| pretreatment docosahexaenoic acid | #3 |
| cultured tryptase | #3 |
| tear il13 | #3 |
| proving type | #3 |
| 005 collagens | #3 |
| techniques tears | #3 |
| sensitivity tear | #3 |
| diabetic corneal disease | #3 |
| benzamidine par2 | #3 |
| conjunctival corneal | #3 |
| dfna control | #3 |
| tears treatment | #3 |
| normal controls collagens | #3 |
| outpatient visits august | #3 |
| patching patient | #3 |
| relevant factor exacerbation | #3 |
| surgery dfna | #3 |
| techniques conjunctivitis | #3 |
| aged elisa | #3 |
| fibronectin vkc | #3 |
| vkc exacerbation | #3 |
| titers ade | #3 |
| par2 cultured | #3 |
| cases vkc | #3 |
| injections keratoconjunctivitis | #3 |
| lacrimal punctal occlusion | #3 |
| samples correlate | #3 |
| rose bengal akc | #3 |
| 01 ophthalmic | #3 |
| differences dfna | #3 |
| underwent staining | #3 |
| vkc fibronectin | #3 |
| corneal ulceration role | #3 |
| par2 benzamidines blotting | #3 |
| mmc excision | #3 |
| vkc long | #3 |
| allergic patients conjunctivitis | #3 |
| weekly average values | #3 |
| eyes vkc | #3 |
| sdedry eye | #3 |
| dibenzoxepins female | #3 |
| giant papilla | #3 |
| pm25 allergic | #3 |
| tear periostin patients | #3 |
| corneal epithelial structure | #3 |
| conjunctivitis benzamidines | #3 |
| cholinergic treatment response | #3 |
| technique uncontrollable | #3 |
| severe allergy patients | #3 |
| treatment skin elasticity | #3 |
| il1beta th2 | #3 |
| higher muc1 eyes | #3 |
| diclofenac eye drops | #3 |
| insensible administration insensible | #3 |
| 21 akc patients | #3 |
| existence par2 mrna | #3 |
| healing allergic | #3 |
| outpatient attendance july | #3 |
| periostin topical | #3 |
| vkc papillae | #3 |
| vkc 5 eyes | #3 |
| conjunctival fibroblasts rtpcr | #3 |
| 3 sjögrens syndrome | #3 |
| mmc authors | #3 |
| akc confocal | #3 |
| aged biological dressings | #3 |
| lnfs nbs | #3 |
| inflammation mmc | #3 |
| akc higher | #3 |
| tear periostin | #3 |
| ari corneal | #3 |
| antibody titers ade | #3 |
| postsurgical conjunctivitis | #3 |
| traumatic swelling | #3 |
| dscg administration | #3 |
| dfna eye | #3 |
| sligkv examined | #3 |
| antiallergic eye drop | #3 |
| treatment oral pilocarpine | #3 |
| conjunctiva conjunctivitis | #3 |
| increased comfort | #3 |
| papillary resection | #3 |
| vkc cell | #3 |
| technique 2 eyes | #3 |
| tryptase conjunctiva | #3 |
| fluorescein glycyrrhizic | #3 |
| nbs subbasal | #3 |
| infrared radiation thermography | #3 |
| 12 akc | #3 |
| tears adolescent | #3 |
| cases vernal | #3 |
| papillary regrowth | #3 |
| flare metry | #3 |
| ecp severity | #3 |
| antieaigg | #3 |
| akc atopic dermatitis | #3 |
| periostin akc | #3 |
| dfna diclofenac epithelium | #3 |
| commercial washing | #3 |
| strip meniscometry testing | #3 |
| local tear deficiency | #3 |
| eye washing | #3 |
| pollen august | #3 |
| eyes control subjects | #3 |
| il1beta th2 cytokines | #3 |
| akc rose bengal | #3 |
| akc periostin | #3 |
| histamine cedar pollen | #3 |
| interleukin4 histamine | #3 |
| allergic conjunctivitis aged | #3 |
| dfna eye dfna | #3 |
| phenomena tacrolimus | #3 |
| elisa histamine | #3 |
| nonpreserved artificial tears | #3 |
| ophthalmic solution nsaid | #3 |
| ulcers eyes | #3 |
| metry dfna | #3 |
| cornea atopic | #3 |
| 111 177 | #3 |
| study cutometer | #3 |
| erosions refractory | #3 |
| conjunctival disease | #3 |
| pm25 outpatient attendance | #3 |
| insufficient tear supply | #3 |
| allergic postsurgical | #3 |
| insufficient tear | #3 |
| permeability postoperatively | #3 |
| portable recordable | #3 |
| oct tmh | #3 |
| 33 chemokines | #4 |
| interferometry lipids | #4 |
| immunologic receptors akc | #4 |
| cornea grading scale | #4 |
| goblet cell muc5ac | #4 |
| eyes sac | #4 |
| corneal temperature blink | #4 |
| implantation thinoptx | #4 |
| vkc normal controls | #4 |
| insignificant epithelial disease | #4 |
| solutions piperidines | #4 |
| vmr 3 months | #4 |
| eyes corneal ulcers | #4 |
| completely severe | #4 |
| rose bengal scores | #4 |
| epithelial muc16 | #4 |
| pathogenesis noninfectious | #4 |
| 3004 respondents | #4 |
| staining muc | #4 |
| photophobia diagnosis | #4 |
| tear function patients | #4 |
| ded 1 | #4 |
| p0001 impression | #4 |
| eye wash solution | #4 |
| surface conjunctival | #4 |
| ophthalmologists eye drops | #4 |
| ophthalmologists evaluated | #4 |
| akc chemotaxis | #4 |
| vkc 4 | #4 |
| samples allergic | #4 |
| samples immunocytochemical | #4 |
| adolescent betamethasone | #4 |
| scores conjunctival | #4 |
| deqs scores | #4 |
| pgd2dependent migration | #4 |
| samples histocytological | #4 |
| chemokine genes fibroblasts | #4 |
| dust wheal | #4 |
| giemsas staining | #4 |
| level conjunctiva | #4 |
| vkc male receptors | #4 |
| sac grade | #4 |
| rsv conjunctival epithelium | #4 |
| tacrolimus conclusions | #4 |
| muc16 muc5ac alterations | #4 |
| epithelial muc | #4 |
| interferometry grade | #4 |
| epithelial disease patients | #4 |
| atopic keratoconjunctivitis purpose | #4 |
| conjunctivitis methods | #4 |
| levocabastine ophthalmic | #4 |
| 061 028 degree | #4 |
| excision papillary | #4 |
| sac control eyes | #4 |
| grade dry eye | #4 |
| akc pgd2dependent migration | #4 |
| rsv allergic reaction | #4 |
| tomography tear | #4 |
| thinoptx | #4 |
| thermography anterior | #4 |
| eyes thinoptx | #4 |
| implantation rollable | #4 |
| lesions regrowth | #4 |
| thinoptx intraocular | #4 |
| membrane patching | #4 |
| acds ophthalmologists | #4 |
| thinoptx lens | #4 |
| allergic patients elisa | #4 |
| male ophthalmic | #4 |
| 2 4 alterations | #4 |
| 2010 allergic | #4 |
| include ocular | #4 |
| akc immunologic receptors | #4 |
| rejection limbal | #4 |
| corneal temperature eye | #4 |
| ocular allergic disease | #4 |
| controls interferometry | #4 |
| eotaxin1 rantes | #4 |
| keratoconjunctivitis lacrimal | #4 |
| mucins 1 | #4 |
| insignificant epithelial | #4 |
| formation conjunctivitis | #4 |
| moisture checker | #4 |
| rsv conjunctiva | #4 |
| il4 tears | #4 |
| sterilized asian dust | #4 |
| tear temperature | #4 |
| controls interferometry grade | #4 |
| pgd2dependent migration eosinophils | #4 |
| inflammation akc | #4 |
| simple resection | #4 |
| atopic dermatitis remission | #4 |
| tears 10 patients | #4 |
| hydrochloride ophthalmic | #4 |
| greater concentrations tears | #4 |
| performed tears | #4 |
| conventional portable | #4 |
| allergies blinding | #4 |
| severe ocular allergies | #4 |
| allergic cytological | #4 |
| corneal safety | #4 |
| staining muc16 | #4 |
| epithelial cells rsv | #4 |
| tryptase dose | #4 |
| controls brush cytology | #4 |
| akc crth2 expression | #4 |
| allergic fibroblasts | #4 |
| persistent 6 | #4 |
| mucin mucins tears | #4 |
| erosion shield | #4 |
| eye sjögrens syndrome | #4 |
| steroids fluorometholone | #4 |
| primary sources chemokines | #4 |
| july pollen | #4 |
| infected conjunctival | #4 |
| folliculosis | #4 |
| patients epithelial disease | #4 |
| eosinophil toxic activity | #4 |
| cultured conjunctival | #4 |
| patients severe vkc | #4 |
| tear function test | #4 |
| ari ono2235 | #4 |
| oedema papillary | #4 |
| papillae normal | #4 |
| akc crth2 | #4 |
| muc5ac brush cytology | #4 |
| cell muc5ac | #4 |
| conjunctiva differences | #4 |
| atopic vernal | #4 |
| topical 01 tacrolimus | #4 |
| exponential equation inclination | #4 |
| ulcers atopic | #4 |
| severe vkc patients | #4 |
| muc16 goblet | #4 |
| metaplasia reduction | #4 |
| metaregression analysis effects | #4 |
| sio2 20 | #4 |
| eye operation | #4 |
| lower tear clearance | #4 |
| epithelial disease eyes | #4 |
| hypersensitivity mucin | #4 |
| conjunctivitis ige | #4 |
| placebo ophthalmic | #4 |
| 4 chemokines stimulation | #4 |
| temperature corneal | #4 |
| cytometry mild cases | #4 |
| fungi epidemiologic studies | #4 |
| acuity akc | #4 |
| ulcers control subjects | #4 |
| muc5ac alterations | #4 |
| tablets tears | #4 |
| tears patients | #4 |
| conjunctivitis levels | #4 |
| akcaffected patients | #4 |
| recordable slit | #4 |
| allergic conjunctivitis rsv | #4 |
| untreated asian dust | #4 |
| months papillary | #4 |
| 0001 brush | #4 |
| allergic conjunctival | #4 |
| muc5ac brush | #4 |
| highrisk glaucoma patients | #4 |
| ocular surface epithelial | #4 |
| underwent corneal | #4 |
| muc5ac mrna expression | #4 |
| patients topical cyclosporine | #4 |
| interferometry controls | #4 |
| eyes akc patients | #4 |
| muc1 2 | #4 |
| genes conjunctival | #4 |
| thermometer 20 | #4 |
| eyes video | #4 |
| topical oral steroids | #4 |
| vkc messenger reverse | #4 |
| pgd2 normal volunteers | #4 |
| allergic conjunctival disease | #4 |
| diameter allergen | #4 |
| mucins tears mucin | #4 |
| histamine h1 antagonist | #4 |
| lower tear function | #4 |
| conjunctivitis vkc | #4 |
| defensins conjunctivitis | #4 |
| fibroblasts primary sources | #4 |
| noninfectious necrotizing | #4 |
| surface muc5ac | #4 |
| corneal sensitivity measurement | #4 |
| healthy individuals rtpcr | #4 |
| clinical conjunctival | #4 |
| special brush | #4 |
| studied corneal | #4 |
| assay pgd2 | #4 |
| par2 mrna protein | #4 |
| drop artificial tears | #4 |
| wilcoxon signed test | #4 |
| specimens underwent | #4 |
| vkc conjunctiva conjunctivitis | #4 |
| conjunctival proliferative | #4 |
| sterilized asian | #4 |
| defensins greater | #4 |
| correlation outpatient | #4 |
| sensation tears | #4 |
| 18 akc patients | #4 |
| epithelial pge2 production | #4 |
| keratoconjunctivitis purpose | #4 |
| staining ocular | #4 |
| disease akc | #4 |
| portable slit | #4 |
| conjunctiva density | #4 |
| stimulation chemokine expression | #4 |
| eyes epithelial disease | #4 |
| subjects muc5ac | #4 |
| ige conjunctival | #4 |
| fva treatment | #4 |
| allergic conjunctival diseases | #4 |
| tears pathogenesis | #4 |
| limbal grafts | #4 |
| 020 013 | #4 |
| rsv conjunctiva conjunctivitis | #4 |
| allergic epidemiologic studies | #4 |
| papillae giant | #4 |
| compared vkc | #4 |
| akc healthy | #4 |
| corneal ulcers eyes | #4 |
| conjunctiva allergic conjunctivitis | #4 |
| aged rose | #4 |
| interferometry 2 | #4 |
| acds conventional | #4 |
| corneal ulcers muc5ac | #4 |
| 10 seconds temperature | #4 |
| bengal sensation | #4 |
| tnfalpha30ng | #4 |
| atopic ocular allergies | #4 |
| patient atopic keratoconjunctivitis | #4 |
| akc healthy individuals | #4 |
| conjunctival papillary | #4 |
| treatment vmr values | #4 |
| corneal sensitivity measurements | #4 |
| microscope evaluating | #4 |
| greater 3 grade | #4 |
| proteinchip array elisa | #4 |
| akc rtpcr | #4 |
| asian dust extract | #4 |
| allergic conjunctivitis prostaglandin | #4 |
| akc sac | #4 |
| dscg day | #4 |
| ulcers mucin | #4 |
| interleukin2 tears | #4 |
| bromfenac ophthalmic | #4 |
| patient eyes fluorescein | #4 |
| 34 15 seconds | #4 |
| eyes ulcers | #4 |
| cells lnfs | #4 |
| epinastine hydrochloride | #4 |
| sensitization asian dust | #4 |
| alterations atopic | #4 |
| crth2 akc | #4 |
| p0001 brush | #4 |
| levocabastine h1 | #4 |
| crth2 peripheral | #4 |
| chemotaxis conjunctiva | #4 |
| atopic ocular | #4 |
| allergic rhinoconjunctivitis allergic | #4 |
| treatment vmr | #4 |
| eosinophils receptor crth2 | #4 |
| trantas | #4 |
| steroids iop | #4 |
| diseases portable | #4 |
| eyes insignificant | #4 |
| weeks vital | #4 |
| cytometry mild | #4 |
| cytology goblet | #4 |
| blinding purpose | #4 |
| pcr epithelial | #4 |
| bromfenac eye drops | #4 |
| individuals pgd2 | #4 |
| thinoptx acrysof | #4 |
| cases sufficient examination | #4 |
| antifungal mcfg | #5 |
| upper palpebral | #5 |
| disease conjunctivitis | #5 |
| postsurgical inflammation | #5 |
| hne ihc | #5 |
| case corneal ulcer | #5 |
| treatment epinastine | #5 |
| ihc conjunctival inflammation | #5 |
| worse akc | #5 |
| schiff immunohistochemical | #5 |
| anterior fluorometry | #5 |
| dryeye symptoms treatment | #5 |
| labeling surface akc | #5 |
| dryeye symptoms | #5 |
| 0001 strip | #5 |
| solution olopatadine | #5 |
| conjunctiva dermatitis | #5 |
| corneal involvement | #5 |
| cells vkc | #5 |
| solutions pollen | #5 |
| crth2 prostaglandin receptors | #5 |
| hel akc | #5 |
| corneal fibroblasts icam1 | #5 |
| akc patients study | #5 |
| 20 sio2 | #5 |
| keratoconjunctivitis giant | #5 |
| tnfα costimulation | #5 |
| 7 conjunctival | #5 |
| stainings tear | #5 |
| akc laser | #5 |
| controls inflammatory cells | #5 |
| allergic conjunctiva conjunctivitis | #5 |
| allergic conjunctivitis patients | #5 |
| intraoperative mitomycin excision | #5 |
| conjunctival allergen | #5 |
| vcam1 fibroblasts | #5 |
| prostaglandin chemotaxis | #5 |
| wilcoxonmatched pair test | #5 |
| vkc atopic | #5 |
| keratoconjunctivitis objective | #5 |
| asthenopia dry | #5 |
| warmer improved | #5 |
| 17 mgd patients | #5 |
| conjunctival inflammatory status | #5 |
| bengal suture | #5 |
| akc acinar | #5 |
| 005 schirmer1 | #5 |
| 3 cases followup | #5 |
| bromobenzenes cornea | #5 |
| schirmer1 test groups | #5 |
| study epinastine | #5 |
| eosinophil adhesion fibroblasts | #5 |
| trantas dots | #5 |
| cytokinestimulation | #5 |
| alpha allergic | #5 |
| diclofenac eye | #5 |
| inflammatory cells hel | #5 |
| impression cytology samples | #5 |
| younger age effects | #5 |
| ophthalmic test | #5 |
| ulcer dermatitis | #5 |
| eosinophils activated fibroblasts | #5 |
| tears received | #5 |
| mcfg eye | #5 |
| simple papillary | #5 |
| cases tests | #5 |
| 329±57 years | #5 |
| temperature blink | #5 |
| severe stevensjohnson syndrome | #5 |
| ophthalmic suspension | #5 |
| conjunctiva mmc | #5 |
| cornea cytodiagnosis | #5 |
| akc hel | #5 |
| pm25 outpatient | #5 |
| adolescent conjunctivitis | #5 |
| meniscus punctal | #5 |
| ulcers controls | #5 |
| conjunctivitis prostaglandin | #5 |
| eosinophil adherence fibroblasts | #5 |
| human conjunctival fibroblasts | #5 |
| allergic keratopathy | #5 |
| adhered corneal | #5 |
| supernatants conjunctival | #5 |
| 01 mcfg | #5 |
| scores expressibility | #5 |
| warmer applied | #5 |
| endophthalmitis eosinophils | #5 |
| eye warmer treatment | #5 |
| pgd2 normal | #5 |
| ocular surface disorder | #5 |
| age 9 ± | #5 |
| layer mgd | #5 |
| conjunctivitis pollen | #5 |
| 5 females akc | #5 |
| situ nickend regulation | #5 |
| lower atopic | #5 |
| local tear | #5 |
| staining administration | #5 |
| visits july | #5 |
| histamine superficial | #5 |
| vkc iop | #5 |
| conventional steroid treatment | #5 |
| eye circulating | #5 |
| 20 akc patients | #5 |
| array chemotaxis | #5 |
| hel ihc | #5 |
| severe conjunctivitis | #5 |
| disposable eyelidwarming device | #5 |
| diseases required | #5 |
| thinoptx iol | #5 |
| allergic drug therapy | #5 |
| akc normal subjects | #5 |
| measurements strip | #5 |
| conjunctival lipid | #5 |
| accompanying allergic | #5 |
| punctal occlusion oct | #5 |
| oct lower | #5 |
| hel cytokines | #5 |
| akc disease | #5 |
| conjunctival confocal microscopy | #5 |
| stimulated conjunctival | #5 |
| regulation allergic cornea | #5 |
| 310±165 years | #5 |
| eosinophils immunologic receptors | #5 |
| crth2 eosinophils | #5 |
| akc ecp | #5 |
| inflammation mitomycin | #5 |
| thiazolidines administration | #5 |
| mitomycin excision | #5 |
| females akc | #5 |
| status confocal | #5 |
| allergic cyclosporine | #5 |
| treatment tacrolimus ointment | #5 |
| eye warmer | #5 |
| scans akc | #5 |
| topical cyclosporine therapy | #5 |
| injection conjunctival | #5 |
| 15 minutes dose | #5 |
| visits august | #5 |
| fibroblasts eosinophil adherence | #5 |
| equipment dry | #5 |
| ocular anesthesia | #5 |
| il4 histamine | #5 |
| cornea explain | #5 |
| alterations ocular | #5 |
| allergic female | #5 |
| anterior scleritis patients | #5 |
| 376±56 years | #5 |
| disposable eyelid | #5 |
| treatment shield | #5 |
| month tear | #5 |
| fibroblasts fibroblast damage | #5 |
| lipid oxidation hel | #5 |
| severity akc | #5 |
| samples akc | #5 |
| lesion corneal | #5 |
| controls ebv | #5 |
| staining muc5ac | #5 |
| ocular allergic | #5 |
| damage impression | #5 |
| pretreatment dha | #5 |
| months amniotic | #5 |
| treatment dryeye symptoms | #5 |
| impression brush | #5 |
| damaged eosinophil | #5 |
| signs akc | #5 |
| stained conjunctival | #5 |
| accompanied varying | #5 |
| tear eosinophil | #6 |
| topical cys treatment | #6 |
| corneal temperature | #6 |
| dermatitis scored | #6 |
| functions topical | #6 |
| rtpcr epithelial cells | #6 |
| bengal vital stainings | #6 |
| samples underwent | #6 |
| topical levocabastine | #6 |
| betamethasone oral | #6 |
| july correlation | #6 |
| conjunctival diseases | #6 |
| tacrolimus chronic | #6 |
| scores goblet | #6 |
| testing tear | #6 |
| akc vernal keratoconjunctivitis | #6 |
| grading tear | #6 |
| tbut vital | #6 |
| severe vkc | #6 |
| agents interferometry | #6 |
| tear stability values | #6 |
| dfna | #6 |
| tryptase proliferation | #6 |
| controlling eyelid | #6 |
| schirmer1 test values | #6 |
| solution commercial | #6 |
| fva landolt | #6 |
| 20 pbs | #6 |
| patients seldi | #6 |
| sde ade | #6 |
| allergic conjunctivitis cac | #6 |
| allergic diathesis | #6 |
| evaporation vital | #6 |
| defect penetrating | #6 |
| inflammatory cell densities | #6 |
| coated elf | #6 |
| ointment blood | #6 |
| cys ocular | #6 |
| cyclosporine 01 | #6 |
| treatment tacrolimus | #6 |
| cgvhd improvements | #6 |
| challenge cac | #6 |
| differences tear | #6 |
| tranilast inhibition | #6 |
| atopic eyelids | #6 |
| diseases periostin | #6 |
| hyperemia imidazoles | #6 |
| pathogenesis ocular | #6 |
| corneal damage | #6 |
| examinations tear | #6 |
| twicedaily instillation | #6 |
| treatment postoperative inflammation | #6 |
| pcr muc5ac | #6 |
| akc refractory | #6 |
| eyes atopic | #6 |
| 4 9 genes | #6 |
| ecp markers | #6 |
| sac vkc | #6 |
| oxidation hel | #6 |
| induced tear | #6 |
| density conjunctival | #6 |
| conjunctival brush cytology | #6 |
| tears acinar | #6 |
| antiallergic eye | #6 |
| ocular surface findings | #6 |
| levels air pollutants | #6 |
| eosinophils crth2 | #6 |
| topical cys | #6 |
| upper tarsal conjunctiva | #6 |
| severe vernal | #6 |
| remodeling vkc | #6 |
| chloride eye | #6 |
| tears xerophthalmia | #6 |
| defect ped | #6 |
| elevation refractory | #6 |
| allergens cedrus | #6 |
| eye evaluated | #6 |
| extract sterilized | #6 |
| conjunctival confocal | #6 |
| strip meniscometry scores | #6 |
| obstructive mgd patients | #6 |
| fluorometholone follow | #6 |
| levocabastine effective | #6 |
| ocular fatigue | #6 |
| syndrome tablets | #6 |
| ade sde | #6 |
| rose bengal dyes | #6 |
| patients visante | #6 |
| dust asian | #6 |
| intolerable irritation | #6 |
| findings dry eye | #6 |
| regulation benzamidines | #6 |
| il4 il2r | #6 |
| signs scored | #6 |
| hyperemia swelling | #6 |
| fibroblasts conjunctival | #6 |
| papillae mucous | #6 |
| noninvasive suction device | #6 |
| edema severity | #6 |
| specimens akc | #6 |
| severe ocular inflammation | #6 |
| 4 muc | #6 |
| dressings female | #6 |
| severe stevens | #6 |
| rate tbut | #6 |
| tear ecp | #6 |
| tear meniscus patients | #6 |
| corneal fibroblasts pathogenesis | #6 |
| elasticity cutometer | #6 |
| concomitant eye | #6 |
| eosinophil recruiting chemokines | #6 |
| itching conjunctival | #6 |
| instability conjunctival | #6 |
| symptoms vkc | #6 |
| conjunctivitis sac | #6 |
| female fluorometholone | #6 |
| eyes ophthalmologists | #7 |
| examination tear | #7 |
| concentrations conjunctival | #7 |
| crth2 normal | #7 |
| hrtii rcm | #7 |
| attendance allergic | #7 |
| increases proliferative | #7 |
| key prostaglandin | #7 |
| corneal lesion | #7 |
| ulceration healthy | #7 |
| hyperemia adverse | #7 |
| pgd2 dependent | #7 |
| tacrolimus topical steroids | #7 |
| mmc observed | #7 |
| necrotizing anterior | #7 |
| normal blinking | #7 |
| conjunctival inflammatory | #7 |
| mucins tears | #7 |
| eyelid surface | #7 |
| severe persistent cases | #7 |
| procedures radioimmunoassay | #7 |
| tear supply | #7 |
| amniotic membrane patching | #7 |
| chemotaxis eosinophils | #7 |
| ulcers revealed | #7 |
| western blotting nfκb | #7 |
| ocular inflammatory disorder | #7 |
| tears alpha | #7 |
| 0001 impression | #7 |
| rose bengal fluorescein | #7 |
| 10 clinical signs | #7 |
| conclusion mmc | #7 |
| sources chemokines | #7 |
| improvements symptom scores | #7 |
| cases preventing | #7 |
| status atopic | #7 |
| conjunctivitis dry | #7 |
| patients comfort level | #7 |
| inhibitor ono2235 | #7 |
| sensation symptom | #7 |
| mucins periodic | #7 |
| pathogenesis subsequent | #7 |
| thought pathogenesis | #7 |
| conjunctival complications | #7 |
| administration fluorescein | #7 |
| papillae formation | #7 |
| allergic dna | #7 |
| nerves tear | #7 |
| development allergic conjunctivitis | #7 |
| solution bf | #7 |
| tacrolimustreated eyes | #7 |
| ulcer corneal | #7 |
| suspension 01 | #7 |
| incidence meibomian | #7 |
| steroidal benzophenones | #7 |
| conjunctivitis risk | #7 |
| conjunctiva brush | #7 |
| revealed eosinophils | #7 |
| collected brush | #7 |
| neutrophils corneal | #7 |
| surgery cooling | #7 |
| cytology differ | #7 |
| silicone plugs | #7 |
| allergic eyelid | #7 |
| evaluation eyelid | #7 |
| age 325 years | #7 |
| injection oedema | #7 |
| tmh measurements | #7 |
| nonparametric tears | #7 |
| adult blepharitis | #7 |
| mmc 005 | #7 |
| prostaglandin atopic | #7 |
| gpc vkc | #7 |
| conjunctival brush | #7 |
| vkc gpc | #7 |
| 4 tear | #7 |
| tears th2 | #7 |
| eczema frequently | #7 |
| sensitization asian | #7 |
| accommodating intraocular lens | #7 |
| superiority placebo | #7 |
| meniscometry testing | #7 |
| alpha tears | #7 |
| pge2 cox2 levels | #7 |
| keratocytes cytokines | #8 |
| noninfectious corneal | #8 |
| palpebral bulbar | #8 |
| 4 chemokines | #8 |
| chemotaxis pgd2 | #8 |
| conjunctival findings | #8 |
| blinking desiccation | #8 |
| akc patients controls | #8 |
| definite dry eye | #8 |
| conjunctival sensation | #8 |
| sac akc | #8 |
| corneal scores | #8 |
| radiation thermography | #8 |
| akc subjects | #8 |
| ulcers detected | #8 |
| techniques keratoconjunctivitis | #8 |
| occlusion lacrimal | #8 |
| corneal ulcer | #8 |
| tnfalpha eosinophils | #8 |
| expressions thought | #8 |
| hoc analysis study | #8 |
| conjunctivitis eyes | #8 |
| blinking body | #8 |
| teros values | #8 |
| meniscometry tear | #8 |
| corneal fibroblasts tnfalpha | #8 |
| eye redness | #8 |
| fluorescein rose bengal | #8 |
| limbalbased conjunctival flap | #8 |
| corneal epithelial lesions | #8 |
| ccl5 conjunctiva | #8 |
| patients corneal | #8 |
| stained hel | #8 |
| staining hel | #8 |
| infrared radiation thermometry | #8 |
| induced intraocular | #8 |
| alterations allergic | #8 |
| ihc hel | #8 |
| allergic dibenzazepines | #8 |
| alterations cornea | #8 |
| diameter acinar | #8 |
| mitomycin post | #8 |
| pollen odds | #8 |
| par2 mast cells | #8 |
| correlation vital | #8 |
| stainings schirmer | #8 |
| rollable intraocular | #8 |
| patients vkc | #8 |
| flare counts | #8 |
| trabeculectomy amniotic | #8 |
| microscopy conjunctival | #8 |
| brush cytology | #8 |
| 006 degree | #8 |
| transient burning sensation | #8 |
| controls seldi | #8 |
| meniscometry scores | #8 |
| asia cats | #8 |
| classified allergic | #8 |
| betamethasone calcineurin | #8 |
| teros | #8 |
| surface teros | #8 |
| oedema scores | #8 |
| controls brush | #8 |
| values slit | #8 |
| superficial cells groups | #8 |
| underwent tear | #8 |
| itching hyperemia | #8 |
| fva measurements | #8 |
| pathogenesis test | #8 |
| scores teros | #8 |
| il4 enzyme | #8 |
| age 170 ± | #8 |
| blink patients | #8 |
| graticule scale | #8 |
| measurements vital | #9 |
| prospective study tacrolimus | #9 |
| specular microscopic evaluation | #9 |
| hyperemia iop | #9 |
| injection edema | #9 |
| pretreatment docosahexaenoic | #9 |
| pilocarpine tablets | #9 |
| acid goblet | #9 |
| differ allergic | #9 |
| cases conjunctivitis | #9 |
| received preserved | #9 |
| inflammation steroidal | #9 |
| pollution conjunctivitis | #9 |
| tacrolimus 95 | #9 |
| eye grade | #9 |
| cys eye | #9 |
| severity corneal | #9 |
| subjective ocular | #9 |
| genes cxc | #9 |
| reductase cataract | #9 |
| vital stainings | #9 |
| superior limbic | #9 |
| stress staining | #9 |
| smart eye | #9 |
| 0001 schirmer | #9 |
| shield ulcers | #9 |
| diagnosis conjunctivitis | #9 |
| conjunctivitis cases | #9 |
| tnfalpha fibroblasts | #9 |
| concentration tears | #9 |
| ono2235 | #9 |
| excision intraoperative | #9 |
| patients tacrolimus treatment | #9 |
| clinical ocular findings | #9 |
| symptoms allergic conjunctivitis | #9 |
| prevalence vkc | #9 |
| sufficient examination | #9 |
| operatedon eye | #9 |
| fatigue dry | #9 |
| fluorescein rose | #9 |
| design eyelid | #9 |
| untreated asian | #9 |
| sio2 pbs | #9 |
| tacrolimus treating | #9 |
| wash solution | #9 |
| blood level tacrolimus | #9 |
| glaucoma younger age | #9 |
| crth2 expression eosinophils | #9 |
| sensitivity conjunctival | #9 |
| elisa tears | #9 |
| prevalence weather | #9 |
| tear level | #9 |
| supply superior | #9 |
| pathogen allergic | #9 |
| histocytological study | #9 |
| sensitivity confocal | #9 |
| observed obstructive | #9 |
| mmc recurrence | #9 |
| conjunctival fibroblast | #9 |
| implantation 1cu | #9 |
| diseases conjunctivitis | #9 |
| foreign body sensation | #9 |
| vital staining scores | #9 |
| tears thermography | #9 |
| hel 4 | #9 |
| cobblestone papillae | #9 |
| level pollutants | #9 |
| eye normal subjects | #9 |
| diagnosis dry eye | #10 |
| allergic conjunctivitis spring | #10 |
| muc5ac muc16 | #10 |
| crth2 chemotaxis | #10 |
| cytometry il4 | #10 |
| muc16 muc5ac | #10 |
| measurement strip | #10 |
| levels tears | #10 |
| eye surface | #10 |
| improvement tear | #10 |
| complain | #10 |
| tear cytology | #10 |
| staining brush | #10 |
| lower tmh | #10 |
| incubated il4 | #10 |
| assessed conjunctival | #10 |
| subbasal stromal | #10 |
| scale tear | #10 |
| topical cyclosporine patients | #10 |
| central graft | #10 |
| substance tears | #10 |
| tears 10 | #10 |
| allergic ocular | #10 |
| icam1 tnfalpha | #10 |
| eye clinically | #10 |
| treatment vkc | #10 |
| cornea eosinophils | #10 |
| staining oral | #10 |
| bengal stainings | #10 |
| functions dry | #10 |
| meibomian gland obstruction | #10 |
| vmr values | #10 |
| humans mucin | #10 |
| laminin actins | #10 |
| underwent slit | #10 |
| leupeptin benzamidine | #10 |
| evaluation atopic | #10 |
| resection regrowth | #10 |
| par2 mast | #10 |
| allergic bronchitis | #10 |
| proliferation conjunctival | #10 |
| conjunctivitis histamine | #10 |
| conjunctivitis atopic | #10 |
| layer alterations | #10 |
| iop hyperemia | #10 |
| shield ulcer | #10 |
| nonallergic conjunctivitis | #10 |
| measuring tear | #10 |
| patients ulcers | #10 |
| eye infrared | #10 |
| compared eyes | #10 |
| conjunctivitis spring | #10 |
| sensation ocular | #10 |
| lacrimal puncta | #10 |
| conjunctivitis japan | #10 |
| punctal occlusion | #10 |
| visante optical | #10 |
| total tear ige | #10 |
| insufficient local | #10 |
| chemokines cxc chemokines | #10 |
| humans conjunctival | #10 |
| status conjunctival | #10 |
| drugs conjunctival | #10 |
| conjunctival edema | #10 |
| produced conjunctival | #10 |
| ophthalmic adolescent | #10 |
| aged conjunctivitis | #10 |
| anesthesia strabismus | #11 |
| count conjunctivitis | #11 |
| purpose metaplasia | #11 |
| eosinophils prostaglandin | #11 |
| patient atopic | #11 |
| smart eye camera | #11 |
| higher muc1 | #11 |
| preserved artificial | #11 |
| surgery 13 eyes | #11 |
| therapy conjunctivitis | #11 |
| lamp microscope | #11 |
| elasticity treatment | #11 |
| common conjunctival | #11 |
| levocabastine hydrochloride | #11 |
| association outpatient | #11 |
| coherence dry | #11 |
| interleukin4 male | #11 |
| diagnosis allergic | #11 |
| schirmer1 test | #11 |
| elisa il4 | #11 |
| keratitis observed | #11 |
| vcam1 tnfalpha | #11 |
| initiation tacrolimus | #11 |
| drop artificial | #11 |
| antivcaigg | #11 |
| test tear | #11 |
| vmr fva | #11 |
| genes corneal | #11 |
| 1 month reduction | #11 |
| palpebral bulbar conjunctiva | #11 |
| weeks papillary | #11 |
| matched dry | #11 |
| vkc | #11 |
| vkc normal | #11 |
| landolt visual | #11 |
| amniotic membrane patch | #11 |
| sensation tear | #11 |
| prevalence dry eye | #11 |
| disease edition | #11 |
| function ocular | #11 |
| sensation staining | #11 |
| ophthalmic solution | #11 |
| vkc adolescent | #11 |
| tears conjunctival | #11 |
| cytometry oligonucleotide | #11 |
| elicited statistically | #11 |
| vernal | #11 |
| fibroblasts pathogenesis | #11 |
| methods conjunctival | #11 |
| hel hne | #11 |
| cooling operation | #11 |
| density acinar | #12 |
| 1821 subjects | #12 |
| corneal shield | #12 |
| 002 ophthalmic | #12 |
| expression 8 genes | #12 |
| keratoplasty glaucoma | #12 |
| appearance atopic | #12 |
| supratarsal injection | #12 |
| radiography tears | #12 |
| acids chemokine | #12 |
| levocabastine patients | #12 |
| conjunctival injection | #12 |
| iop younger | #12 |
| 001 specimens | #12 |
| ccl11 conjunctiva | #12 |
| receptor crth2 | #12 |
| iop glucocorticoids humans | #12 |
| microscopy efficient | #12 |
| coated lactoferrin | #12 |
| surface diabetic | #12 |
| selected severity | #12 |
| extracts pollens | #12 |
| highspeed highresolution | #12 |
| specimens eyes | #12 |
| eye diagnosed | #12 |
| 1cu iol | #12 |
| fva vmr | #12 |
| keratoconjunctivitis patients | #12 |
| cornea density | #12 |
| lacrimal punctal | #12 |
| mmhg elevation | #12 |
| tears conjunctivitis | #12 |
| pemirolast potassium | #12 |
| findings conjunctival | #12 |
| drugs pge2 | #12 |
| damage height | #12 |
| corneal aesthesiometry | #12 |
| immunologic rejection | #12 |
| projects tears | #12 |
| severe binocular | #12 |
| conventional slit | #12 |
| density muc5ac | #12 |
| fluorescein scores | #12 |
| biomarker allergic | #12 |
| dermatitis tacrolimus | #12 |
| 1cu accommodating | #12 |
| controls antibody titers | #12 |
| fva visual | #12 |
| leupeptins mast | #12 |
| ulcers squamous | #12 |
| patients sac | #12 |
| mgd controls | #12 |
| scraped samples | #13 |
| blood levels tacrolimus | #13 |
| fluorometholone fml | #13 |
| temperature cataract | #13 |
| coherence viscosupplements | #13 |
| week corneal | #13 |
| glaucoma younger | #13 |
| schirmers test values | #13 |
| remodeling relevant | #13 |
| ulcers corneal | #13 |
| thirty eyes | #13 |
| time fluorescein | #13 |
| inflammation tear | #13 |
| objective signs | #13 |
| improvement vital | #13 |
| called giant | #13 |
| vmr measurements | #13 |
| conjunctival oedema | #13 |
| tear hel | #13 |
| keratocytes incubated | #13 |
| epithelial disease | #13 |
| glaucoma keratoplasty | #13 |
| upper tarsal | #13 |
| dry eye examination | #13 |
| papillary samples | #13 |
| cell flare | #13 |
| symptoms conjunctival | #13 |
| anterior segment photography | #13 |
| topical cyclosporine treatment | #13 |
| suspensions tacrolimus | #13 |
| applied operation | #13 |
| tear functions | #13 |
| stability vital | #13 |
| syndrome reactivation | #13 |
| chemokines stimulation | #13 |
| outcomes 01 | #13 |
| months healed | #13 |
| specimens levels | #13 |
| sd105 | #13 |
| corneal complications | #13 |
| bengal fluorescein | #13 |
| treatment allergic conjunctivitis | #13 |
| 5ac ophthalmic | #13 |
| interferometry tear | #13 |
| protein conjunctival | #13 |
| aged disposable | #13 |
| japan keratoconjunctivitis | #13 |
| compared postsurgical | #13 |
| conclusions ocular | #13 |
| pilocarpine effective | #14 |
| higher allergic | #14 |
| eyes 002 | #14 |
| conjunctivitis vernal | #14 |
| visits allergic | #14 |
| conjunctival muc5ac | #14 |
| clinically allergic | #14 |
| vehicle eye | #14 |
| epithelial muc5ac | #14 |
| conjunctivitis background | #14 |
| cornea endophthalmitis | #14 |
| conjunctival impression | #14 |
| schirmer1 | #14 |
| fungi adolescent | #14 |
| secrete mediators | #14 |
| fluorometholone humans | #14 |
| density tear | #14 |
| conjunctival allergen challenge | #14 |
| solutions retrospective | #14 |
| benzamidines blotting | #14 |
| bf 01 | #14 |
| mcfg treatment | #14 |
| dry eye controls | #14 |
| factors conjunctivitis | #14 |
| functions corneal | #14 |
| flare count | #14 |
| radioimmunoassay tears | #14 |
| fibroblast damage | #14 |
| test rose | #14 |
| 14 flare | #14 |
| clinical corneal | #14 |
| occlusion dry | #14 |
| proliferative lesion | #14 |
| blinking patients | #14 |
| day bf | #15 |
| basal tear secretion | #15 |
| adherence fibroblasts | #15 |
| investigated corneal | #15 |
| mucous discharge | #15 |
| occlusion rose | #15 |
| analysis par2 | #15 |
| improvement corneal | #15 |
| improvement subjective symptoms | #15 |
| occlusion oct | #15 |
| ocular surface mucins | #15 |
| corneal recurrence | #15 |
| ophthalmology tokyo | #15 |
| irritation scores | #15 |
| ulcer echinocandins | #15 |
| eye drop treatment | #15 |
| diseases 2020 | #15 |
| correlation tear | #15 |
| superior conjunctiva | #15 |
| ocular itching | #15 |
| complications mmc | #15 |
| bilateral conjunctivitis | #15 |
| giant papillary | #15 |
| evaluation conjunctival | #15 |
| bromobenzenes child | #15 |
| ocular acrylic | #15 |
| agents blepharitis | #15 |
| examined existence | #15 |
| expression realtime pcr | #15 |
| damaged fibroblasts | #15 |
| topical 01 | #15 |
| vkc methods | #15 |
| surface vital | #15 |
| olopatadine 01 | #15 |
| mmc female follow | #15 |
| patients vernal | #15 |
| tranilast anti | #15 |
| effects benzalkonium | #15 |
| steroidal cornea | #15 |
| complications height | #15 |
| tmh values | #15 |
| rtpcr cytometry | #15 |
| blepharitis conjunctivitis | #15 |
| monitoring tear | #15 |
| ige ecp | #15 |
| receptor pgd2 | #15 |
| firstline drug | #15 |
| cytology brush | #15 |
| safety 01 | #16 |
| alpha ortho | #16 |
| fungi odds | #16 |
| measurements tear | #16 |
| ulcers positive | #16 |
| controls papillary | #16 |
| hours visit | #16 |
| treatment eyelid | #16 |
| odds ratio remission | #16 |
| total clinical scores | #16 |
| reduction goblet | #16 |
| temperature conjunctiva | #16 |
| segment photography | #16 |
| lacrimation | #16 |
| objective ocular | #16 |
| assessment conjunctival | #16 |
| 2 conjunctival | #16 |
| ari administration | #16 |
| eosinophils receptor | #16 |
| ige correlation | #16 |
| dust allergic | #16 |
| female goblet | #16 |
| patients vernal keratoconjunctivitis | #16 |
| warmer treatment | #17 |
| strip meniscometry | #17 |
| fibroblasts damaged | #17 |
| inhibitor ari | #17 |
| eyes schirmer | #17 |
| inflammation blotting | #17 |
| evaluation inflammatory | #17 |
| signs ded | #17 |
| drops eyes | #17 |
| corneal sensation | #17 |
| clearance corneal | #17 |
| expression eotaxin1 | #17 |
| muc16 mrna | #17 |
| meniscometry | #17 |
| wear soft | #17 |
| agents cedrus | #17 |
| ocular allergic inflammation | #17 |
| age dry | #17 |
| conjunctival samples | #17 |
| sclera trabeculectomy | #17 |
| ceramide gel | #17 |
| initiation objective | #17 |
| 13 females age | #17 |
| analyzed 005 | #17 |
| 20 normal patients | #17 |
| betamethasone induced | #17 |
| increased goblet cells | #17 |
| staining muc1 | #17 |
| fibroblasts mcp1 | #17 |
| ocular surface status | #18 |
| concentrations corneal | #18 |
| studies rose | #18 |
| cytology decrease | #18 |
| conclusion ocular | #18 |
| cd45 inflammatory | #18 |
| groups spt | #18 |
| associations level | #18 |
| tear evaporation rate | #18 |
| bengal sjogren | #18 |
| complete staining | #18 |
| lower eyes | #18 |
| ulceration subjects | #18 |
| rantes response | #18 |
| differentiation inflammatory cells | #18 |
| dibenzazepines dibenzoxepins | #18 |
| fibroblasts giant | #18 |
| correlation clinical signs | #18 |
| intraoperative 002 | #18 |
| inflammation lenses | #18 |
| pollen fungi | #18 |
| higher tears | #18 |
| tear function | #18 |
| technique glaucoma | #18 |
| male ophthalmic solutions | #18 |
| decrease ocular | #18 |
| tnfα inflammatory response | #18 |
| 30 ige | #18 |
| test tears | #18 |
| evaluation tear | #18 |
| cytology corneal | #18 |
| obstructive dysfunction | #18 |
| noncl wearers | #18 |
| ulcers compared | #18 |
| induce corneal | #18 |
| types dry eye | #18 |
| trabeculectomy glaucoma | #18 |
| measurements visante | #19 |
| ige tear | #19 |
| sma performed | #19 |
| temperature artificial | #19 |
| periostin biomarker | #19 |
| outpatient attendance | #19 |
| vernal keratoconjunctivitis | #19 |
| 1151 years | #19 |
| mitomycin ophthalmologic | #19 |
| subjects underwent | #19 |
| dha pretreatment | #19 |
| steroid female | #19 |
| eosinophils adhered | #19 |
| sodium 01 | #19 |
| total signs | #19 |
| early efficacy | #19 |
| aged ophthalmic | #19 |
| human conjunctival | #19 |
| operation applied | #19 |
| 3 severe | #19 |
| evaluated infrared | #19 |
| conjunctivitis topical | #19 |
| microscopy scans | #19 |
| prospective study eyes | #19 |
| effective tacrolimus | #19 |
| beta1 il1beta | #19 |
| staining scores | #19 |
| limbal allograft | #19 |
| inflammatory cells patients | #19 |
| seldi proteinchip | #19 |
| aged cautery | #19 |
| seldi analysis | #19 |
| plaques graded | #20 |
| common ocular disorders | #20 |
| conjunctivitis caused | #20 |
| symptoms allergic | #20 |
| lower dry | #20 |
| bilateral agerelated cataract | #20 |
| proteins tears | #20 |
| decreased conjunctival | #20 |
| cytology upper | #20 |
| allergic female humans | #20 |
| patients strip | #20 |
| improvements ocular | #20 |
| echinocandins eye | #20 |
| persistent epithelial defect | #20 |
| explain pathogenesis | #20 |
| pollen association | #20 |
| conclusion tacrolimus | #20 |
| height tmh | #20 |
| corneal impression | #20 |
| 022 pg | #20 |
| conjunctivitis primary | #20 |
| ulcers cell | #20 |
| treated 01 | #20 |
| tears corneal | #20 |
| xerophthalmia adolescent | #20 |
| surface findings | #20 |
| mucin alterations | #20 |
| summarized based | #20 |
| vernal keratoconjunctivitis vkc | #20 |
| evaluate noninferiority | #20 |
| lipid oxidative | #21 |
| methane nonmethane hydrocarbons | #21 |
| patients cedar | #21 |
| cultured conjunctiva | #21 |
| tears blood | #21 |
| eosinophils flow cytometry | #21 |
| reduction topical | #21 |
| film lipid | #21 |
| acuity assessment | #21 |
| symptoms include | #21 |
| radiation thermometer | #21 |
| eye smaller | #21 |
| keratoconjunctivitis atopic | #21 |
| conjunctiva role | #21 |
| fluorescence postoperative | #21 |
| microscopy patients | #21 |
| levels hel | #21 |
| cornea clinical | #21 |
| induced topical | #21 |
| crth2 expressed | #21 |
| reaction tears | #21 |
| conclusions topical | #21 |
| ocular symptoms signs | #21 |
| preventing corneal | #21 |
| adhesion fibroblast | #21 |
| eye control | #21 |
| patients concomitant treatment | #21 |
| peripheral blood eosinophils | #21 |
| surface mucin | #21 |
| ige groups | #21 |
| accommodation amplitude | #22 |
| haze photorefractive | #22 |
| eyes nerve | #22 |
| flare anterior | #22 |
| fluorescein staining | #22 |
| types ocular | #22 |
| therapies allergic | #22 |
| correlation humidity | #22 |
| serum periostin patients | #22 |
| 01 tacrolimus | #22 |
| epithelial lipid | #22 |
| muc5ac patients | #22 |
| mgd adult | #22 |
| fibroblasts anti | #22 |
| 005 topical | #22 |
| negative lower | #22 |
| solution corneal | #23 |
| subjects squamous | #23 |
| blood concentration tacrolimus | #23 |
| tests adenovirus | #23 |
| lamp examinations | #23 |
| palpebral conjunctiva | #23 |
| il4 tnf | #23 |
| cooling applied | #23 |
| function mucin | #23 |
| corneal fluorescein | #23 |
| solution compared | #23 |
| hrt confocal | #23 |
| diseases diclofenac | #23 |
| tear dynamics | #23 |
| preschool conjunctivitis | #23 |
| prospectively surgery | #23 |
| 01 severe | #23 |
| score deqs | #23 |
| disease atopic | #23 |
| layer interferometry | #23 |
| 215 ± | #23 |
| patients topical steroids | #23 |
| labeling tears | #23 |
| 5 females | #23 |
| pge2 supernatants | #23 |
| edema drug | #24 |
| bengal tears | #24 |
| formation allergic | #24 |
| ocular allergies | #24 |
| surface tear | #24 |
| control tear | #24 |
| histamine development | #24 |
| diseases web | #24 |
| dermatitis improved | #24 |
| tarsal conjunctiva | #24 |
| 27yearold male patient | #24 |
| patients tacrolimus ointment | #24 |
| cell meter | #24 |
| local allergic reaction | #24 |
| fungal corneal | #24 |
| interleukin4 oligonucleotide | #24 |
| tokyo dental | #24 |
| signs serum | #24 |
| vital staining | #24 |
| layer tear | #24 |
| conjunctiva diabetes | #24 |
| vkc patients | #24 |
| samples conjunctival | #24 |
| warming device | #24 |
| 0001 dry | #25 |
| density squamous | #25 |
| vkc compared | #25 |
| dynamics tear | #25 |
| steroid eye | #25 |
| rsv rtpcr | #25 |
| staining goblet | #25 |
| rtpcr rsv | #25 |
| eyes epithelial | #25 |
| slitlamp examinations | #25 |
| vcam1 activated | #25 |
| antigen conjunctiva | #25 |
| schedule eosinophil | #25 |
| superficial cells | #25 |
| confocal prospective | #25 |
| level tears | #25 |
| patients atopic diseases | #25 |
| atopic eosinophils humans | #25 |
| bengal scores | #25 |
| corneal plaques | #25 |
| protein rtpcr | #25 |
| rapid epithelialization | #26 |
| keratoconjunctivitis caused | #26 |
| damage adhesion | #26 |
| symptoms itching | #26 |
| singletreatment groups | #26 |
| diseases ambient | #26 |
| solutions corneal | #26 |
| tbut tear | #26 |
| 01 topical | #26 |
| conclusions improvement | #26 |
| human α defensin | #26 |
| corneal ulcers | #26 |
| specific ige positivity | #26 |
| eyes topical | #26 |
| 100 nylon | #26 |
| conjunctivitis | #26 |
| slit lamp examinations | #26 |
| acinar unit | #26 |
| adhered fibroblasts | #26 |
| actins collagen | #26 |
| lnfs | #26 |
| treatment meibomian | #26 |
| smallincision cataract surgery | #26 |
| level il4 | #26 |
| aureus detected | #26 |
| postkeratoplasty glaucoma | #26 |
| 005 immunoreactive | #26 |
| subjects measuring | #26 |
| conjunctival inflammation | #26 |
| correlated corneal | #26 |
| wheal diameter | #26 |
| dmem f12 medium | #26 |
| statistical decrease | #26 |
| antibodies brush | #27 |
| factor exacerbation | #27 |
| eosinophils fibroblasts | #27 |
| child cytological | #27 |
| tear ocular | #27 |
| lymphocytes specimens | #27 |
| therapy conjunctiva | #27 |
| 01 cyclosporine | #27 |
| interleukin4 polymerase | #27 |
| 005 symptoms | #27 |
| associations prevalence | #27 |
| oct prospective | #27 |
| alpha eosinophils | #27 |
| density subbasal | #27 |
| conjunctival epithelial | #27 |
| reaction sensation | #27 |
| cytometry chemotaxis | #27 |
| epinastine | #27 |
| prescribed topical | #27 |
| assay eosinophils | #28 |
| severe ocular | #28 |
| provide relief | #28 |
| conjunctival epithelial cells | #28 |
| diseases proliferative | #28 |
| 2 iol | #28 |
| 4 5ac | #28 |
| chemotactic activity eosinophils | #28 |
| papillae patients | #28 |
| ophthalmic | #28 |
| solutions ophthalmologic | #28 |
| corneal vivo | #28 |
| eosinophil adherence | #28 |
| corneal ulceration | #28 |
| giant papillae | #28 |
| objective scores | #28 |
| conjunctiva dexamethasone | #28 |
| assessment tear | #28 |
| il13 il1beta | #28 |
| underwent immunohistochemical | #28 |
| prevalence allergic diseases | #28 |
| stress atopic | #28 |
| disease periostin | #29 |
| eye mask | #29 |
| numbers inflammatory | #29 |
| 5ac mucins | #29 |
| rosebengal | #29 |
| inhibited tranilast | #29 |
| sac compared | #29 |
| thermography adolescent | #29 |
| ketotifen fumarate | #29 |
| conjunctiva dose | #29 |
| flare cell | #29 |
| studies conjunctivitis | #29 |
| scores schirmer | #29 |
| corneal conjunctival | #29 |
| cys treatment | #29 |
| allergic regulation | #29 |
| aged thermography | #29 |
| performed morphometric | #29 |
| ocular surface alterations | #30 |
| symptoms accompanying | #30 |
| fibroblasts protease | #30 |
| tear ige | #30 |
| atopic diagnostic | #30 |
| inhibitors pollen | #30 |
| mucins ophthalmic | #30 |
| common adverse reaction | #30 |
| eye common | #30 |
| il2r serum | #30 |
| effective artificial | #30 |
| minutes visit | #30 |
| regrowth observed | #30 |
| dermatitis efficacy | #30 |
| tear serum | #30 |
| specificity tears | #30 |
| palpebral | #30 |
| recruitment day | #30 |
| expressed crth2 | #30 |
| redness eye | #30 |
| syndromes equipment | #30 |
| conjunctivitis patients | #30 |
| conjunctiva cells | #30 |
| infection conjunctival | #30 |
| conjunctivitis humans | #30 |
| worse observed | #31 |
| dermatitis purpose | #31 |
| scores corneal | #31 |
| levels july | #31 |
| fibroblasts pcr | #31 |
| disease summarized | #31 |
| acuity fva | #31 |
| expressed eosinophils | #31 |
| combinations eosinophils | #31 |
| meibomian gland secretion | #31 |
| vegf cultured | #31 |
| properties tears | #31 |
| pathogenesis corneal | #31 |
| ige negative | #31 |
| schirmer scores | #31 |
| epithelial mucins | #31 |
| inflammation atopic | #31 |
| atopic 10 | #31 |
| neutrophils severity | #31 |
| hel levels | #31 |
| deqs | #32 |
| schirmer test values | #32 |
| signs improved | #32 |
| sign scores | #32 |
| western blotting effects | #32 |
| reduced steroid | #32 |
| analysis tears | #32 |
| limbus cornea | #32 |
| eye sjögren | #32 |
| tear meniscus height | #32 |
| conjunctival cells | #32 |
| substantial interrater agreement | #32 |
| prostaglandin cell | #32 |
| diagnosed dry | #32 |
| keratoconjunctivitis | #32 |
| expressibility | #32 |
| tgfbeta1 il1beta | #32 |
| muc 1 | #33 |
| levocabastine | #33 |
| conclusions confocal | #33 |
| numbers quantitative | #33 |
| atopic skin disease | #33 |
| ige histamine | #33 |
| signs evaluated | #33 |
| edema correlated | #33 |
| haze score | #33 |
| seasonal young | #33 |
| count prostaglandin | #33 |
| iop induced | #33 |
| film break | #33 |
| 4 grades | #33 |
| immunoglobulin interferometry | #33 |
| allergic double | #33 |
| visante | #33 |
| bengal staining | #34 |
| intraocular pressure surgery | #34 |
| alpha fibroblasts | #34 |
| eye 10 | #34 |
| fluorometholone glucocorticoids | #34 |
| il1beta tgfbeta1 | #34 |
| treatment mgd | #34 |
| fibroblasts purpose | #34 |
| 10 objective | #34 |
| eyes corneal | #34 |
| therapy histamine | #34 |
| proteinchip array | #34 |
| conjunctiva cytokines | #34 |
| 01 effective | #34 |
| clinical signs patients | #34 |
| hypertension tacrolimus | #35 |
| mucins prospective | #35 |
| cyclosporine cys | #35 |
| virus capsid antigen | #35 |
| 6 months conclusion | #35 |
| adult asthenopia | #35 |
| interrater reproducibility | #35 |
| objective symptoms | #35 |
| tear stability | #35 |
| eye 20 | #35 |
| measured tear | #36 |
| differential dry | #36 |
| humans keratoconjunctivitis | #36 |
| functional visual acuity | #36 |
| anterior scleritis | #36 |
| schirmer 1 | #36 |
| eyes acrysof | #36 |
| resection 005 | #36 |
| severe allergic | #36 |
| tear clearance | #36 |
| tear samples | #36 |
| efficacy groups | #36 |
| vdt users | #36 |
| ocular surface inflammation | #36 |
| diseases eosinophil | #36 |
| scleritis episcleritis | #37 |
| oct effective | #37 |
| delefilcon | #37 |
| induced iop | #37 |
| eyelid skin | #37 |
| laser flarecell meter | #37 |
| tenon anesthesia | #37 |
| tears tumor | #37 |
| schirmer 1 test | #37 |
| recurrence corneal | #37 |
| conducted compliance | #37 |
| wellrecognized risk | #37 |
| contact lens surface | #37 |
| 002 mmc | #37 |
| tacrolimus 12 | #37 |
| gland lipid | #38 |
| cac japanese | #38 |
| 002 mitomycin | #38 |
| allergic cromolyn | #38 |
| phacoemulsification implantation | #38 |
| aged olopatadine | #38 |
| device eye | #38 |
| post cataract | #38 |
| pemirolast | #38 |
| exhibited correlation | #38 |
| cells conjunctiva | #39 |
| solutions patient | #39 |
| tests diagnostic accuracy | #39 |
| response pretreatment | #39 |
| cyclosporine dry | #39 |
| 0001 specimens | #39 |
| degree 20 | #39 |
| conjunctiva limbus | #39 |
| 005 oct | #39 |
| tears eye | #39 |
| atopic dry | #39 |
| accommodating intraocular | #39 |
| patients dry eye | #39 |
| infiltration corneal | #39 |
| ulcers control | #40 |
| samples eyes | #40 |
| eye patients | #40 |
| acid chemokine | #40 |
| biomarkers conjunctiva | #40 |
| pharmacology clinical efficacy | #40 |
| tmh | #40 |
| drops corneal | #40 |
| decreased inflammation | #40 |
| endothelial rejection | #40 |
| subjects specimens | #40 |
| homologous visual | #41 |
| conjunctivitis gpc | #41 |
| treatment dry | #41 |
| ecp concentrations | #41 |
| stimulate vascular | #41 |
| α pge2 | #41 |
| treated topical | #41 |
| pollution severe | #41 |
| eyes superior | #41 |
| vegf il1beta | #41 |
| il1beta vegf | #41 |
| epitheliopathy | #41 |
| scans underwent | #42 |
| october july | #42 |
| efficient noninvasive | #42 |
| break time | #42 |
| corneal epithelia | #42 |
| day eye | #42 |
| allergens conjunctivitis | #42 |
| meniscus treatment | #43 |
| revised 2010 | #43 |
| instability decreased | #43 |
| diseases 2017 | #43 |
| rollable | #43 |
| conjunctival hyperemia | #43 |
| keratolimbal | #43 |
| surface years | #43 |
| limbus corneal | #43 |
| hydrocarbons data | #43 |
| microscopy central | #43 |
| eyelid edema | #43 |
| cytology revealed | #43 |
| tacrolimus treatment | #44 |
| oct assessment | #44 |
| epithelial defect | #44 |
| subjective symptom | #44 |
| tryptase par2 | #44 |
| tear meniscus | #44 |
| patients rhinoconjunctivitis | #44 |
| il1beta il4 | #44 |
| cautery female | #44 |
| elasticity patients | #44 |
| eye 0001 | #44 |
| agents keratoconjunctivitis | #44 |
| abovementioned drugs | #44 |
| collagens fibronectin | #44 |
| activated il4 | #44 |
| rose bengal staining | #45 |
| users contact | #45 |
| surface inflammation | #45 |
| metaplasia mucin | #45 |
| bovine enteric | #45 |
| understanding ocular | #45 |
| body sensation | #45 |
| superficial punctate keratitis | #45 |
| case corneal | #45 |
| signs score | #45 |
| recruiting chemokines | #45 |
| graded 3 | #45 |
| fourgrade scale | #45 |
| fibroblasts expression | #45 |
| inflammation ocular surface | #45 |
| metaplasia grade | #45 |
| elevation iop | #45 |
| laser microscopy | #45 |
| 24 seconds | #45 |
| fibroblasts eosinophils | #45 |
| surgery uncorrected | #45 |
| japan particulate | #45 |
| adult chemotaxis | #45 |
| micafungin mcfg | #45 |
| correlation inflammation | #45 |
| topical tacrolimus treatment | #45 |
| formation corneal | #45 |
| 17 japanese patients | #46 |
| suspension effective | #46 |
| tryptases regulation | #46 |
| staining conjunctival | #46 |
| surface disease | #46 |
| fluorometholone | #46 |
| il13 serum | #46 |
| efficacy combined therapy | #46 |
| seconds controls | #46 |
| posttreatment findings | #46 |
| conjunctival | #46 |
| status ocular | #46 |
| corneal cells | #46 |
| graticule | #46 |
| staining inflammatory | #46 |
| efficacy 01 | #46 |
| visante oct | #47 |
| blood level | #47 |
| diameter plant | #47 |
| allergic female histamine | #47 |
| ulcer score | #47 |
| positive muc5ac | #47 |
| suspension 4 | #47 |
| purpose efficacy | #47 |
| rate ocular | #47 |
| patients 01 | #47 |
| enhanced benefits | #48 |
| stromal nerve | #48 |
| eyes month | #48 |
| muc5ac mrna | #48 |
| cyclosporine ophthalmic | #48 |
| implantation acrysof | #48 |
| complications corneal | #48 |
| sac patients | #48 |
| stimulation chemokine | #48 |
| dexamethasone anti | #48 |
| eyelid warming | #48 |
| brush cytology specimens | #48 |
| keratocytes fibroblasts | #49 |
| ocular signs | #49 |
| trabeculectomy eyes | #49 |
| adult ca125 | #49 |
| concentrations tears | #49 |
| male tears | #49 |
| objective findings | #49 |
| 1cu | #49 |
| fibroblasts incubated | #49 |
| eosinophils epithelium | #49 |
| cxc chemokine genes | #49 |
| visits air | #49 |
| expression crth2 | #49 |
| tacrolimus female | #49 |
| test ocular | #50 |
| patient eyes | #50 |
| trabeculectomy mitomycin | #50 |
| dyes fluorophotometry | #50 |
| disposable soft | #50 |
| measuring corneal | #50 |
| schirmers test | #50 |
| decreased tear | #50 |
| total severity score | #50 |
| ulcers purpose | #50 |
| inflammation conjunctiva | #50 |
| aged blinking | #50 |
| meniscus height | #50 |
| 4 normal controls | #50 |
| scls | #51 |
| crth2 expression | #51 |
| reduction score | #51 |
| inflammation cataract | #51 |
| markers atopic | #51 |
| cells brush | #51 |
| effects docosahexaenoic acid | #51 |
| members japan | #51 |
| diagnosis dry | #51 |
| periostin patients | #51 |
| lenses scls | #51 |
| ocular surface cells | #51 |
| biomarker diseases | #52 |
| pcr tgf | #52 |
| severity objective | #52 |
| tears tomography | #52 |
| eye normal | #52 |
| inflammation decline | #52 |
| reaction vehicle | #52 |
| stability corneal | #52 |
| atopic groups | #52 |
| examination parameters | #52 |
| eyelid margins | #52 |
| month initiation | #52 |
| differential eosinophil | #53 |
| stromal nerves | #53 |
| acuity values | #53 |
| bromfenac | #53 |
| scores tear | #54 |
| 005 month | #54 |
| lacrimal glands | #54 |
| suspension treatment | #54 |
| chloride bak | #54 |
| vegf protein secretion | #54 |
| oxidation adolescent | #54 |
| limbic keratoconjunctivitis | #54 |
| obstructive mgd | #54 |
| presence rsv | #54 |
| atopic enterotoxins | #55 |
| combinedtreatment | #55 |
| ocular signs symptoms | #55 |
| conjunctiva drug | #55 |
| epithelial cells expression | #55 |
| aged pollen | #55 |
| local cytokine production | #55 |
| surface clinical | #55 |
| adult conjunctivitis | #55 |
| antagonists allergic | #55 |
| 3 dry | #56 |
| pain photophobia | #56 |
| plant pollens | #56 |
| cornea cyclooxygenase | #56 |
| mucin layer | #56 |
| allergies adolescent | #56 |
| eosinophil cationic | #56 |
| mechanism giant | #56 |
| mucin2 mucin4 | #56 |
| solution placebo | #56 |
| film ocular | #56 |
| atopic patients | #56 |
| specular microscopic | #56 |
| dysfunction atopic | #56 |
| ded adult | #56 |
| topical adolescent | #56 |
| penetrating limbus | #57 |
| giant papillary conjunctivitis | #57 |
| inflammation pge2 | #57 |
| chemotactic responses | #57 |
| insensible administration | #57 |
| humans interleukin4 | #57 |
| accommodating iol | #57 |
| schiff staining | #58 |
| objective sign | #58 |
| maximum blood concentration | #58 |
| papilla formation | #58 |
| alpha defensins | #58 |
| staining tear | #58 |
| drop treatment | #58 |
| seventyeight eyes | #58 |
| tear instability | #59 |
| intraoperative mitomycin | #59 |
| findings criteria | #59 |
| type allergic | #59 |
| pm25 prevalence | #59 |
| disease eyes | #59 |
| signs severe | #60 |
| pcr severe | #60 |
| syndromes female | #60 |
| tacrolimus ointment treatment | #60 |
| diabetic corneal | #60 |
| release inhibitor | #60 |
| mmc 2 | #60 |
| compared 0001 | #60 |
| daily disposable | #60 |
| evaluation items | #60 |
| correlation patients | #61 |
| thermography adult | #61 |
| punctal | #61 |
| nonsteroidal blotting | #61 |
| specimens histopathologic | #62 |
| eyes 16 | #62 |
| amplitude accommodation | #62 |
| allergen mediated | #62 |
| combination epithelium | #62 |
| prostaglandin patients | #62 |
| values tended | #62 |
| total clinical | #62 |
| expression eyes | #62 |
| eotaxin1 expression | #62 |
| hypersensitivity japan | #63 |
| patient corneal | #63 |
| chamber body | #63 |
| oral pilocarpine | #63 |
| conjunctiva patients | #63 |
| micafungin treatment | #63 |
| corneal erosion | #63 |
| il4 role | #63 |
| corneal stem | #63 |
| ulcer endophthalmitis | #63 |
| sac age | #63 |
| cornea dry | #64 |
| density inflammatory | #64 |
| evaluation corneal | #64 |
| dexamethasone production | #64 |
| factor allergic | #64 |
| radioimmunoassay respiratory | #64 |
| il4 culture | #64 |
| positive mucin | #64 |
| eye adolescent | #64 |
| dust house | #65 |
| microscope methods | #65 |
| viral radioimmunoassay | #65 |
| mucins rna | #65 |
| live rsv | #65 |
| tears biomarkers | #65 |
| conclusions corneal | #65 |
| cases atopic | #66 |
| surface epithelial | #66 |
| treatment immunosuppressive agents | #66 |
| layer speed | #66 |
| diagnosis therapies | #66 |
| effects 01 | #67 |
| female fluorophotometry | #67 |
| period oral | #67 |
| agents keratoplasty | #67 |
| cyclosporine eye | #67 |
| 003 treatment | #67 |
| persistent epithelial | #67 |
| housedust | #68 |
| time vital | #68 |
| eye dry | #68 |
| ointment treatment | #68 |
| patients eosinophils | #69 |
| counter drugs | #69 |
| glaucoma graft | #69 |
| ophthalmic solutions | #69 |
| aged tears | #69 |
| occlusion 005 | #69 |
| fibroblasts examined | #69 |
| fibroblasts corneal | #69 |
| visit 4 | #70 |
| schirmer test | #70 |
| crth2 receptor | #70 |
| 22 eyes | #70 |
| rhinoconjunctivitis allergic | #70 |
| 1436 patients | #70 |
| crth2 pgd2 | #70 |
| values rose | #70 |
| factors tears | #71 |
| dust 20 | #71 |
| drops treatment | #71 |
| lenses dry | #71 |
| allergic dermatitis | #71 |
| tear production | #72 |
| glaucoma trabeculectomy | #72 |
| ige eosinophil | #72 |
| 16 eyes | #72 |
| bulbar conjunctiva | #72 |
| fluorophotometry humans | #73 |
| pyridines pyrimidinones | #73 |
| punctate keratopathy | #73 |
| immunosuppressive treatment patients | #73 |
| antiallergic agent | #73 |
| surface mucins | #73 |
| epithelial structure | #73 |
| extraction conjunctiva | #73 |
| pollution prevalence | #73 |
| liquid conjunctiva | #73 |
| fml | #73 |
| mcfg | #74 |
| iol acrysof | #74 |
| tacrolimus patients | #74 |
| agents intraocular | #74 |
| evaluation dry | #74 |
| inflammatory cell numbers | #74 |
| eosinophils expressed | #74 |
| healthy individuals patients | #75 |
| cedar pollen | #75 |
| improved infrared | #75 |
| dust epidemiologic | #75 |
| pilocarpine prospective | #75 |
| completely controlled | #75 |
| laser flare | #75 |
| 1 month baseline | #75 |
| agents interleukin4 | #76 |
| guidelines allergic | #76 |
| interleukin4 rna | #76 |
| ccchemokine | #76 |
| surgery technique | #77 |
| cornea module | #77 |
| capilia | #77 |
| chemical mediator | #77 |
| cytology samples | #77 |
| studies suspensions | #77 |
| signs treatment | #77 |
| vegf tgfbeta1 | #77 |
| slight elongation | #77 |
| cytokines stimulate | #77 |
| lower tear | #77 |
| ophthalmological elasticity | #77 |
| excision recurrence | #77 |
| concomitant tacrolimus | #78 |
| concentration il2 | #78 |
| drops 1 | #78 |
| pollen compared | #78 |
| japanese guideline | #78 |
| signs observed | #78 |
| severity ocular | #78 |
| permeability cornea | #79 |
| allergic environmental | #79 |
| type allergy | #79 |
| glaucoma penetrating | #79 |
| il4 ige | #79 |
| extended wear | #79 |
| effects corneal | #79 |
| ocular pain | #79 |
| dry eye | #79 |
| injection reduction | #79 |
| inhibitors leupeptin | #79 |
| medications required | #80 |
| assay epithelial | #80 |
| mgd patients | #80 |
| mediated par2 | #80 |
| questionnaires tears | #80 |
| antigens histamine | #81 |
| decreased dry | #81 |
| vegf concentration | #81 |
| prostaglandin reverse | #82 |
| caused insufficient | #82 |
| patients conjunctivitis | #82 |
| acrysof iol | #82 |
| atopic dermatitis study | #82 |
| cytology performed | #82 |
| expression corneal | #83 |
| complications lenses | #83 |
| data tacrolimus | #83 |
| patients staphylococcus aureus | #83 |
| tear lipid | #83 |
| dental college | #83 |
| epithelium ocular | #84 |
| papillae | #84 |
| cytokines vegf | #84 |
| earlier published data | #84 |
| correlation corneal | #84 |
| schirmer | #84 |
| alterations basal | #85 |
| treatment odds ratio | #85 |
| 5 grades | #85 |
| inhibitors tryptases | #85 |
| combined penetrating | #85 |
| temperature patients | #85 |
| scleritis patients | #85 |
| human reverse | #85 |
| patients dry | #85 |
| hyperemia induced | #85 |
| 18 pg | #85 |
| discharge evaluated | #86 |
| daily outpatient | #86 |
| inflammation eye | #86 |
| patients eyelid | #86 |
| sligkv | #86 |
| edema scores | #86 |
| pharmacologic intervention | #86 |
| 284 years | #86 |
| acuity accommodation | #86 |
| confocal ophthalmic | #87 |
| tacrolimus young | #87 |
| detection limit assay | #87 |
| tacrolimus reduced | #87 |
| daily weather conditions | #88 |
| cells keratocytes | #88 |
| regulation muc5ac | #88 |
| disease conjunctiva | #88 |
| post keratoplasty | #88 |
| sclera surgical | #88 |
| tears | #88 |
| seasonal perennial | #89 |
| tears visual | #89 |
| eyes 30 | #89 |
| findings severe | #89 |
| assessment dry | #89 |
| tryptase inhibitors | #89 |
| lower corneal | #90 |
| glands microscopy | #90 |
| early ocular | #90 |
| cytocentrifuge preparations | #90 |
| dressings chronic | #90 |
| decrease corneal | #90 |
| months signs | #90 |
| tears adult | #90 |
| temperature cornea | #90 |
| lenses extended | #91 |
| film breakup | #91 |
| exposure japan | #92 |
| laser cell | #92 |
| eye corneal | #92 |
| techniques trabeculectomy | #92 |
| procedures phacoemulsification | #92 |
| 005 complications | #93 |
| conjunctival specimens | #93 |
| stromal corneal | #93 |
| 7 visit | #93 |
| eye cataract surgery | #93 |
| treatment noninfectious | #93 |
| patients correlation | #93 |
| regulation muc1 | #93 |
| solutions tears | #93 |
| tears administration | #93 |
| drug fibroblasts | #93 |
| preschool conjunctiva | #93 |
| reaction physical | #94 |
| pollution weather | #94 |
| exposure exhaust | #94 |
| case allergic | #94 |
| classification pathogenesis | #94 |
| pgd2 crth2 | #94 |
| induced pgd2 | #95 |
| eosinophils patients | #95 |
| eye higher | #95 |
| studies tears | #95 |
| relevant factor | #95 |
| twentyeight eyes | #95 |
| 128 eyes | #96 |
| higher eyes | #96 |
| staining fluorescein | #96 |
| protein eosinophilia | #96 |
| score objective | #96 |
| study cyclosporine | #96 |
| production pge2 | #97 |
| cells hel | #97 |
| treatment ecp | #97 |
| 1month treatment | #97 |
| 4 alterations | #97 |
| vdts | #98 |
| staining schirmer | #98 |
| eye tear | #98 |
| eyes positive | #98 |
| meniscus patients | #98 |
| eyes study | #98 |
| equivalent 4 | #99 |
| surgery 6 months | #99 |
| cytology evaluation | #99 |
| japan post | #99 |
| solution improved | #99 |
| 005 recurrence | #99 |
| pseudophakic patients | #99 |
| management ocular | #99 |
| confocal scanning | #100 |
| allergic atopic | #100 |
| local pattern | #100 |
| conjunctiva corneal | #100 |
| corneal abnormalities | #100 |
| terminals contact | #100 |
| postoperatively statistically | #100 |
| cells severity | #100 |
| ulcer patient | #100 |
| ointments tacrolimus | #100 |
| pathogenesis atopic | #101 |
| fibroblasts 2 | #101 |
| eyes 10 | #101 |
| effects tranilast | #102 |
| disease classified | #102 |
| agents conjunctivitis | #102 |
| severe atopic | #102 |
| therapy conjunctival | #102 |
| pathogenesis allergic | #102 |
| keratolimbal allograft | #102 |
| subjective comfort | #103 |
| mediated protease | #103 |
| prevalence dry | #103 |
| chemotaxis experiments | #103 |
| washing solution | #103 |
| allergic cytokines | #104 |
| groups dry | #104 |
| patients bf | #104 |
| values vital | #104 |
| differences ocular | #104 |
| syndrome epstein | #104 |
| topical cyclosporine | #104 |
| events scores | #104 |
| tears young | #104 |
| topic premedication | #104 |
| child conjunctival | #105 |
| inflammation diagnosis | #105 |
| baseline initiation | #105 |
| wearing contact | #105 |
| role staphylococcal | #105 |
| aged amnion | #105 |
| conjunctival impression cytology | #105 |
| 14 eyes | #106 |
| conjunctiva cornea | #106 |
| adhesion fibroblasts | #106 |
| pressure keratoplasty | #106 |
| microscopy evaluation | #106 |
| parameters ocular | #106 |
| corneal keratocytes | #107 |
| eotaxin1 | #107 |
| superficial punctate | #107 |
| patients ded | #107 |
| induces chemotaxis | #108 |
| resins aged | #108 |
| dry mouth symptoms | #108 |
| conjunctiva | #108 |
| lipid layer | #108 |
| film instability | #108 |
| levels radioimmunoassay | #108 |
| acuity acrylic | #108 |
| topical tacrolimus | #108 |
| scores symptoms | #108 |
| il4 human | #109 |
| corneal inflammatory | #109 |
| asian dust | #109 |
| 4 dry | #109 |
| tear evaporation | #109 |
| effects dha | #109 |
| level tacrolimus | #109 |
| increased evaporation | #110 |
| dysfunction mgd | #110 |
| lacrimal salivary | #110 |
| japanese guidelines | #110 |
| eyes 9 | #110 |
| conjunctival epithelium | #110 |
| steroids administration | #110 |
| controls inflammatory | #110 |
| topical instillation | #111 |
| severity markers | #111 |
| vcam1 antibody | #112 |
| eye camera | #112 |
| dibenzoxepins | #113 |
| pcr rsv | #113 |
| strabismus surgery | #113 |
| papillary conjunctivitis | #113 |
| anterior segment inflammation | #113 |
| solutions platelet | #113 |
| eye irritation | #114 |
| grading scores | #114 |
| incision cataract | #114 |
| lesions atopic | #114 |
| layer patients | #114 |
| diagnosed allergic | #114 |
| male mucin | #115 |
| cholinergic treatment | #115 |
| goblet cell density | #115 |
| findings severity | #115 |
| allergic eye | #115 |
| 13 eyes | #115 |
| conjunctival cell | #115 |
| sjögrens syndrome patients | #115 |
| seconds 0001 | #115 |
| edition revised | #116 |
| selective histamine | #116 |
| viscosupplements aged | #117 |
| samples stained | #117 |
| asia dust | #117 |
| metaplasia mucins | #117 |
| cooling increased | #117 |
| patients seasonal | #117 |
| ophthalmology prevalence | #117 |
| effects docosahexaenoic | #118 |
| molecule1 interleukin4 | #118 |
| immunologic receptors prostaglandin | #118 |
| sag genes | #118 |
| generation pge2 | #118 |
| chemotaxis induced | #119 |
| iop observed | #119 |
| acuity distance | #119 |
| 39 mmhg | #119 |
| revealed higher | #119 |
| skin elasticity | #119 |
| topical steroids | #119 |
| week 005 | #119 |
| syndromes epithelium | #120 |
| matter prevalence | #120 |
| soft lenses | #121 |
| mitomycinc mmc | #121 |
| levels histamine | #121 |
| mitomycin ophthalmic | #121 |
| distance corrected | #121 |
| chronic allergic | #122 |
| artificial tear | #123 |
| adult conjunctiva | #123 |
| titers ebv | #123 |
| collagen conjunctiva | #123 |
| male ointments | #123 |
| eosinophils cell | #124 |
| area corneal | #124 |
| conjunctival tissues | #125 |
| activity corneal | #125 |
| proteaseactivated receptor2 | #126 |
| damage severe | #126 |
| month reduced | #126 |
| 05ng | #127 |
| patients atopic | #127 |
| nerves studied | #127 |
| subjects vivo | #127 |
| 9 genes | #128 |
| soft contact lenses | #128 |
| gamma increase | #128 |
| acds | #129 |
| elisa levels | #129 |
| combination steroids | #129 |
| 361 ± | #129 |
| fibroblast viability | #129 |
| functional visual | #130 |
| fva | #130 |
| patients insignificant | #130 |
| antigen hladr | #131 |
| disease cornea | #131 |
| 5ac | #132 |
| resection severe | #132 |
| management allergic | #132 |
| eyes fluorescein | #132 |
| eye drop | #132 |
| cataract phacoemulsification | #132 |
| keratoplasty adult | #133 |
| skin water | #133 |
| 19 normal subjects | #133 |
| proteins mucin | #133 |
| treated tacrolimus | #133 |
| gene transcription levels | #133 |
| density negative | #134 |
| pcr hla | #134 |
| acrylic iol | #134 |
| surface examination | #134 |
| normal conjunctival | #134 |
| specimens vivo | #135 |
| solutions phacoemulsification | #135 |
| stress status | #136 |
| iop treatment | #136 |
| eosinophil adhesion | #137 |
| antiallergic properties | #137 |
| severity 10 | #137 |
| ocular surface | #137 |
| ophthalmological dry | #137 |
| dry eye patients | #137 |
| eosinophil cationic protein | #138 |
| asian dust storms | #138 |
| iol groups | #138 |
| ratio remission | #139 |
| allergic dogs | #139 |
| authors technique | #139 |
| protein ecp | #139 |
| suppressed pretreatment | #140 |
| inflammation prostaglandin | #141 |
| aminobenzoates anti | #141 |
| allergic patients | #141 |
| findings upper | #142 |
| interleukin1 interleukin13 | #142 |
| improvements symptom | #142 |
| combination rapid | #143 |
| olopatadine hydrochloride | #143 |
| determine central | #144 |
| 52 mmhg | #144 |
| cornea cyclosporine | #144 |
| studies scleritis | #144 |
| eye syndromes | #145 |
| symptoms ocular | #145 |
| specimens patient | #145 |
| recordable | #145 |
| schiff reaction | #146 |
| eye clinical | #146 |
| reticular basement membrane | #146 |
| findings adolescent | #146 |
| fibroblasts alpha | #146 |
| human conjunctiva | #146 |
| virus pathogen | #146 |
| underwent evaluation | #146 |
| required type | #147 |
| impression cytology | #147 |
| hne 4 | #147 |
| diagnosis atopic | #147 |
| dscg | #147 |
| 263 years | #147 |
| 0001 corneal | #148 |
| increased goblet | #148 |
| ulcer drug | #148 |
| dynamic visual acuity | #148 |
| fibroblasts production | #149 |
| concentration tacrolimus | #149 |
| japan phenotype | #149 |
| suspension based | #149 |
| patients allergic | #149 |
| intraocular lens iol | #149 |
| quantitative evaluation | #149 |
| cationic protein | #149 |
| japanese cedar pollen | #150 |
| inflammatory cells | #150 |
| pyrimidinones treatment | #150 |
| inflammation reduction | #151 |
| controls performed | #151 |
| tacrolimus treated | #152 |
| postoperative secondary | #152 |
| par2 reverse | #152 |
| eyes 11 | #153 |
| increased fibroblasts | #153 |
| induced eotaxin | #153 |
| artificial tears | #153 |
| 28 surgery | #153 |
| symptoms objective | #153 |
| concentrations il4 | #154 |
| inflammation ocular | #155 |
| male mitomycin | #155 |
| grade effects | #155 |
| chemokine expression | #156 |
| association pm25 | #156 |
| alcon | #156 |
| eyelids female | #156 |
| pcr increase | #157 |
| ointments skin | #157 |
| inflammatory ocular | #157 |
| greater inflammation | #157 |
| rates untreated | #157 |
| analysis prostaglandin | #157 |
| values improved | #157 |
| lipid infiltration | #157 |
| japan included | #158 |
| surface status | #158 |
| trial tacrolimus | #158 |
| acuities | #158 |
| weeks adverse | #159 |
| 3 boys | #159 |
| immunological characteristics | #159 |
| study inflammation | #160 |
| muc16 | #161 |
| thirtysix eyes | #161 |
| 28 female | #161 |
| mucin 5ac | #161 |
| chemokines production | #161 |
| elevation study | #161 |
| acid schiff | #161 |
| 326 years | #162 |
| surgery topical | #162 |
| male meibomian | #162 |
| bromobenzenes | #162 |
| distance visual acuity | #162 |
| visit 7 | #163 |
| il1beta il2 | #163 |
| twentynine eyes | #163 |
| studied 21 | #163 |
| olopatadine | #163 |
| efficacy tacrolimus | #163 |
| oxidative stress status | #163 |
| prevalence ocular | #163 |
| spt positive | #164 |
| steroid anti | #164 |
| purpose reported | #164 |
| patients topical | #164 |
| 002 treatment | #164 |
| 30ng | #164 |
| soft contact | #164 |
| biological dressings | #165 |
| production prostaglandin | #165 |
| pgd2 induced | #166 |
| cytometry hla | #166 |
| fluorescein humans | #166 |
| cytokines allergic | #167 |
| tacrolimus ointment | #167 |
| eosinophils higher | #167 |
| males 5 | #168 |
| ulcers erosions | #168 |
| patients postsurgical | #169 |
| 12 males | #169 |
| seldi | #169 |
| steroidal blotting | #169 |
| treating refractory | #169 |
| studies tacrolimus | #169 |
| eotaxin chemokine | #169 |
| local allergic | #169 |
| expression chemokines | #170 |
| status inflammation | #171 |
| conjunctiva conjunctival | #171 |
| management enzyme | #171 |
| subbasal nerve | #172 |
| fibroblasts fibroblast | #173 |
| palisades | #173 |
| distance acuity | #174 |
| subjective symptoms | #174 |
| status oxidative | #174 |
| vivo confocal | #174 |
| standard conventional | #174 |
| slit lamp | #174 |
| pcr flow | #174 |
| postkeratoplasty | #175 |
| 34 eyes | #175 |
| evaluated symptoms | #176 |
| homologous molecule | #176 |
| aldehydes biomarkers | #177 |
| treatment corneal | #177 |
| subbasal | #177 |
| dust extract | #177 |
| study longterm outcomes | #177 |
| acrysof | #178 |
| mild 2 | #178 |
| endophthalmitis female | #178 |
| reduction intraocular pressure | #178 |
| strabismus adolescent | #178 |
| tryptase | #178 |
| risk ocular | #179 |
| chemokine genes | #179 |
| japan young adult | #180 |
| ceramides child | #180 |
| migration eosinophils | #180 |
| compared eye | #180 |
| myopic regression | #180 |
| dyes follow | #180 |
| 4 female | #180 |
| normal control patients | #181 |
| lipid study | #181 |
| cutometer | #181 |
| serum il4 | #183 |
| blepharitis | #183 |
| lipoproteins micafungin | #183 |
| male radioallergosorbent | #184 |
| igg virus | #185 |
| mucin4 mucins | #185 |
| human lymphocyte antigen | #185 |
| nerve prospective | #186 |
| therapy corneal | #186 |
| examined parameters | #186 |
| atopic eosinophils | #187 |
| drug fibroblasts humans | #187 |
| efficacy topical | #187 |
| suspensions administration | #187 |
| par2 mrna | #187 |
| corneal fibroblasts | #187 |
| eye symptoms | #188 |
| 19 eyes | #188 |
| corneal sensitivity | #188 |
| il13 increased | #188 |
| allergic cross | #189 |
| seconds patients | #189 |
| sensitivity regulation | #189 |
| production stromal | #189 |
| levels 33 | #190 |
| effects diesel | #191 |
| infiltrating eosinophils | #191 |
| tear break | #191 |
| assisted infrared | #191 |
| improvement subjective | #192 |
| therapeutic study | #193 |
| controls vivo | #193 |
| allergic rhinoconjunctivitis | #193 |
| 26 eyes | #194 |
| reactivation epstein | #195 |
| fibroblasts inhibited | #195 |
| expression rantes | #195 |
| rigid gas | #196 |
| female histamine | #196 |
| methods primary | #197 |
| eyes 21 | #197 |
| 80 allergens | #197 |
| tear film stability | #197 |
| treatment topical | #197 |
| interleukin4 production | #197 |
| tears time | #198 |
| elisa performed | #198 |
| 28 eyes | #198 |
| combination topical | #198 |
| effects topical | #199 |
| pollen prospective | #199 |
| photorefractive keratectomy | #201 |
| perennial allergic | #201 |
| mcp1 ip10 | #201 |
| pollen allergic | #201 |
| preservative free | #201 |
| receptor homologous | #202 |
| unit density | #202 |
| hypersensitivity interleukin13 | #202 |
| rsv infected | #202 |
| eosinophils neutrophils | #203 |
| ova alum | #204 |
| differences iop | #204 |
| grade scale | #204 |
| vcam1 icam1 | #204 |
| pge2 human | #204 |
| inflammatory allergic | #205 |
| eyes 005 | #205 |
| disease acd | #206 |
| time tbut | #206 |
| disease dry | #206 |
| minutes 8 | #206 |
| eyes cataract | #206 |
| count cornea | #207 |
| ecp levels | #207 |
| glands middle | #207 |
| formation giant | #207 |
| pressure lens | #207 |
| crth2 | #207 |
| tears aged | #208 |
| fluorescein fluorescent | #208 |
| mammalian milk | #208 |
| size contact | #208 |
| uncorrected corrected | #209 |
| analysis pm25 | #209 |
| human allergic | #210 |
| treatment allergic | #210 |
| month reduction | #210 |
| antiallergic drug | #211 |
| oct diagnosis | #211 |
| refractory conventional | #211 |
| combination tests | #212 |
| inflammation injection | #212 |
| iol patients | #212 |
| tacrolimus combination | #212 |
| chamber anti | #213 |
| conjunctiva eye | #213 |
| treated refractory | #213 |
| muc5ac | #214 |
| steroids treatment | #214 |
| alpha il4 | #215 |
| ige higher | #216 |
| conjunctival goblet | #217 |
| allergic agents | #217 |
| worse eyes | #218 |
| lens purpose | #218 |
| expressions higher | #219 |
| nuclear cataract | #219 |
| metabolism lysine | #220 |
| tranilast | #220 |
| august october | #220 |
| conjunctival biopsy | #220 |
| findings inflammation | #221 |
| conjunctivitis acute | #221 |
| level ambient | #222 |
| combined therapy | #222 |
| diseases dry | #222 |
| samples correlated | #222 |
| cells crth2 | #222 |
| twentyfour eyes | #222 |
| iop corneal | #224 |
| 26 control subjects | #224 |
| symptoms short | #224 |
| sensitivity measurements | #224 |
| allergic drug | #225 |
| patients eye | #226 |
| 17 eyes | #227 |
| eyes adult | #228 |
| treatment 3 months | #228 |
| corneal clarity | #228 |
| itching | #229 |
| followup cases | #229 |
| corrected distance | #230 |
| eye signs | #230 |
| treatment superior | #230 |
| activity eosinophils | #231 |
| exhaust particles | #231 |
| 30 eyes | #231 |
| alpha defensin | #232 |
| examined level | #232 |
| events initiation | #232 |
| scleral flap | #232 |
| 791 patients | #233 |
| concomitantly administered | #233 |
| proteinchip | #233 |
| anti allergic | #233 |
| cyclosporine treatment | #233 |
| dye staining | #233 |
| 644 years | #234 |
| cultured eosinophils | #235 |
| examined production | #235 |
| quantitatively evaluate | #236 |
| corneal disease | #236 |
| specimens patients | #236 |
| term topical | #237 |
| gamma transcripts | #237 |
| topical steroid | #238 |
| proliferative lesions | #240 |
| diagnostic abilities | #240 |
| studied subjects | #240 |
| tool quantitative | #240 |
| bf patients | #241 |
| eyes ocular | #241 |
| cell chemotactic | #242 |
| cromolyn sodium | #242 |
| surface lipid | #242 |
| common ocular | #245 |
| performed higher | #245 |
| specular microscopy | #246 |
| equivalent 2 | #247 |
| eye drops | #247 |
| subjects males | #247 |
| chemosis | #248 |
| specificity cutoff | #248 |
| failure visual | #250 |
| labeling intercellular | #251 |
| response prostaglandin | #251 |
| subjective objective | #252 |
| males 13 | #252 |
| seasonal allergic | #252 |
| syndrome tears | #252 |
| leukocyte child | #252 |
| topical oral | #253 |
| levels tacrolimus | #253 |
| improved vision | #255 |
| muc | #255 |
| corneal female | #255 |
| rantes expression | #256 |
| stability positive | #256 |
| dexamethasone inhibition | #256 |
| treating severe | #257 |
| disease corneal | #257 |
| eosinophil chemotaxis | #258 |
| tear | #259 |
| questionnaire objective | #259 |
| month treatment | #260 |
| eyes control | #260 |
| additional medications | #260 |
| eosinophil infiltration | #260 |
| role histamine | #260 |
| expression rsv | #261 |
| human transcription | #261 |
| h1 antagonist | #262 |
| smaller normal | #262 |
| immunohistochemistry increased | #264 |
| 1 month treatment | #264 |
| aged mucin | #264 |
| severity adverse | #264 |
| steroid induced | #265 |
| keratoplasty pkp | #265 |
| eyelid diseases | #266 |
| controls p0001 | #266 |
| data weekly | #267 |
| signs blood | #267 |
| microscopy negative | #268 |
| treatment atopic | #268 |
| patients sjögren syndrome | #268 |
| studied production | #268 |
| respiratory syncytial virus | #268 |
| sodium drug | #269 |
| computer terminals | #270 |
| aged aldehyde | #270 |
| h1 histamine | #270 |
| dry eye symptoms | #271 |
| prevalence allergic | #272 |
| 13 males | #273 |
| aldose reductase inhibitor | #273 |
| improved visual acuity | #273 |
| studies stevens | #274 |
| concentration quantitative | #274 |
| epithelium endothelium | #274 |
| combination eosinophils | #274 |
| meibomian gland dysfunction | #275 |
| meibomian gland | #277 |
| patients sjögren | #277 |
| tear breakup time | #277 |
| tbut | #278 |
| grading score | #278 |
| individuals pcr | #278 |
| 0001 diagnosis | #279 |
| 13 females | #279 |
| bloodaqueous barrier | #279 |
| eyes 14 | #279 |
| interleukin il4 | #280 |
| multifunctional glycoprotein | #280 |
| 10 seconds | #281 |
| required provide | #281 |
| cautery | #282 |
| disease purpose | #282 |
| expressed th2 | #282 |
| gland dysfunction | #284 |
| ige positive | #284 |
| amniotic membrane | #285 |
| contralateral eye | #285 |
| seasons adolescent | #286 |
| atopic | #286 |
| th2 cytokines | #287 |
| cases refractory | #288 |
| layer adult | #288 |
| study tacrolimus | #289 |
| adult alkylating | #289 |
| eyedrops | #291 |
| entericcoated | #291 |
| water child | #292 |
| iop glaucoma | #293 |
| new antifungal | #294 |
| treatment 01 | #294 |
| exponential equation | #294 |
| serum periostin | #295 |
| levels ige | #295 |
| single therapy | #295 |
| surgery statistically | #297 |
| hyperemia | #297 |
| seventy eyes | #299 |
| ccl11 chemokine | #300 |
| rose bengal | #300 |
| severity diagnosis | #300 |
| pkp | #301 |
| benzalkonium chloride | #301 |
| morphologic alterations | #302 |
| assessed based | #303 |
| cobblestone | #303 |
| moderate 3 | #303 |
| scanning laser | #304 |
| photophobia | #304 |
| operation patient | #305 |
| scores worse | #305 |
| initiation treatment | #305 |
| eczema severity | #306 |
| piperidines treatment | #306 |
| membrane patch | #307 |
| assessed 4 | #307 |
| gel application | #308 |
| 10 normal subjects | #309 |
| evaluation groups | #309 |
| interleukin13 interleukin2 | #309 |
| compared simple | #310 |
| inflammatory cell | #310 |
| comfort level | #310 |
| cytology specimens | #311 |
| regard age | #311 |
| 12 eyes | #311 |
| treatment seasonal | #311 |
| slitlamp examination | #311 |
| 7 eyes | #312 |
| molecules chronic | #313 |
| aged staining | #315 |
| eye adult | #315 |
| child corneal | #316 |
| 19 normal | #316 |
| interferometry light | #317 |
| cells cornea | #317 |
| analysis glaucoma | #318 |
| values lower | #319 |
| dermatitis clinical | #320 |
| prospective singlearm study | #320 |
| fluorophotometry | #320 |
| cells chemotaxis | #321 |
| il8 rantes | #321 |
| bilateral cataracts | #323 |
| ulcers | #323 |
| agreement weighted | #324 |
| pollen allergen | #324 |
| eyes 19 | #325 |
| 15 30 minutes | #325 |
| icam1 vcam1 expression | #326 |
| 095 ± | #326 |
| chemokine concentrations | #327 |
| surgery diabetic | #327 |
| transplantation corneal | #328 |
| expression goblet | #329 |
| icam1 antibody | #329 |
| insensible | #330 |
| pressure ocular | #331 |
| treatment 2 weeks | #331 |
| dry eye disease | #332 |
| receptors il2r | #332 |
| leukocyte coculture | #333 |
| cornea diagnostic | #335 |
| eye treated | #335 |
| values daily | #335 |
| proprietary | #336 |
| 27 eyes | #337 |
| corneal epithelial | #337 |
| male staphylococcal | #337 |
| signs clinical | #339 |
| daily wear | #339 |
| levels epithelial | #341 |
| eyes 27 | #341 |
| methods eyes | #342 |
| asthenopia | #343 |
| illness tacrolimus | #344 |
| limbus | #346 |
| corneal infection | #347 |
| measurements treatment | #347 |
| expression eosinophils | #348 |
| induced elevation | #348 |
| eyes 13 | #348 |
| test values | #350 |
| surgery eye | #350 |
| contrast visual | #352 |
| surface diseases | #352 |
| iop elevation | #353 |
| expression allergic | #354 |
| weekly average | #354 |
| incidence allergic | #355 |
| temperature infrared | #355 |
| choroidal detachment | #356 |
| examination serum | #356 |
| tear film | #357 |
| patients allergy | #357 |
| eyes 8 | #358 |
| local cytokine | #358 |
| tacrolimus tumor | #359 |
| months conventional | #359 |
| subjects 13 | #361 |
| difference efficacy | #361 |
| agents benzophenones | #362 |
| messenger blotting | #363 |
| aureus patients | #363 |
| injections lidocaine | #364 |
| studies sclera | #368 |
| function laser | #368 |
| plant pollen | #368 |
| treatment ocular | #368 |
| corneae male | #369 |
| mucin1 mucin2 | #370 |
| eyes 17 | #370 |
| postoperative adhesion | #370 |
| systemic control | #371 |
| cryptomeria japonica | #372 |
| inhibitors epithelium | #372 |
| sixteen eyes | #373 |
| periodic acid schiff | #374 |
| micafungin middle | #374 |
| cornea female | #375 |
| improvement local | #375 |
| assessment severe | #375 |
| extraction cell | #376 |
| retina tomograph | #376 |
| 4 lower | #377 |
| levels atopic | #377 |
| phacoemulsification prospective | #377 |
| higher human | #377 |
| 10 normal | #377 |
| treatment eyes | #378 |
| tarsal | #378 |
| count child | #378 |
| stimulation tnf | #380 |
| mitomycin | #380 |
| corneal inflammation | #381 |
| cornea eye | #381 |
| negative serum | #382 |
| inflammation epithelial | #383 |
| pollinosis | #383 |
| examinations including | #384 |
| gas permeable | #384 |
| vivo corneal | #385 |
| ocular diseases | #386 |
| corneal epithelial cells | #386 |
| limit assay | #388 |
| surface alterations | #388 |
| decrease inflammatory | #388 |
| surgery 13 | #388 |
| healing adult | #389 |
| cells vehicle | #389 |
| severity incidence | #390 |
| sde | #390 |
| patients proteins | #391 |
| antiallergic | #391 |
| breakup time | #393 |
| immunohistochemistry tests | #394 |
| 44 eyes | #395 |
| applied 5 | #395 |
| chronic ocular | #395 |
| opacity corneal | #396 |
| relative percentages | #396 |
| techniques interleukin4 | #396 |
| apparatus lacrimal | #397 |
| expression lower | #397 |
| increased understanding | #398 |
| ocular surface disease | #399 |
| pressure elevation | #399 |
| declaration helsinki | #400 |
| remission based | #400 |
| modified boyden | #401 |
| eyes severe | #401 |
| rays male | #402 |
| sedating humans | #403 |
| measurements oct | #404 |
| cells allergic | #404 |
| vogt | #404 |
| weather air | #404 |
| prospective controlled study | #405 |
| patients epithelial | #406 |
| reproducibility surface | #406 |
| improved diagnosis | #407 |
| serum total ige | #407 |
| 137 years | #407 |
| postoperative aged | #408 |
| activated fibroblasts | #409 |
| heidelberg retina tomograph | #410 |
| acids fibroblasts | #412 |
| specific total | #412 |
| confocal | #412 |
| eyes 15 | #412 |
| 3 months treatment | #413 |
| counts 1 | #413 |
| allergic reaction | #413 |
| keratocytes | #414 |
| postoperative inflammation | #416 |
| limbal | #416 |
| central cornea | #418 |
| penetrating keratoplasty | #418 |
| chemokine ccl11 | #419 |
| mucin4 | #419 |
| speed resolution | #419 |
| patients comfort | #419 |
| sjögren syndrome | #420 |
| ophthalmologist | #420 |
| lacrimal gland | #422 |
| 20 normal controls | #424 |
| 40 minutes | #425 |
| clinical observation | #425 |
| production 4 | #430 |
| trabeculectomy visual | #430 |
| staining score | #431 |
| rhinoconjunctivitis | #431 |
| 0 normal | #433 |
| subjects atopic | #434 |
| performed immunohistochemistry | #437 |
| cedrus | #437 |
| methods eye | #438 |
| regulation eye | #438 |
| 5 women | #438 |
| commercial tests | #439 |
| interleukin4 il4 | #440 |
| foldable | #440 |
| subjects studied | #440 |
| vmr | #441 |
| regulation chemokine | #441 |
| fluorescein dye | #441 |
| landolt | #441 |
| adult aldehydes | #442 |
| anti vcam1 | #442 |
| females normal | #442 |
| 17 males | #444 |
| male mucin1 | #444 |
| patients combined therapy | #445 |
| 39 consecutive patients | #447 |
| air pollution data | #448 |
| dogs dust | #448 |
| 30 serum | #450 |
| male 4 | #450 |
| eye eyes | #451 |
| keratoplasty | #452 |
| wash | #452 |
| versus vehicle | #453 |
| antagonists sedating | #453 |
| ketotifen | #453 |
| vivo confocal microscopy | #454 |
| surface disorder | #454 |
| normal patients | #454 |
| response allergens | #454 |
| 8 genes | #455 |
| water evaporation | #455 |
| production clearance | #455 |
| ophthalmic nerve | #455 |
| humans keratoplasty | #456 |
| agonists pilocarpine | #456 |
| outpatient visits | #457 |
| ocular risk | #457 |
| amnion cell | #457 |
| normal controls patients | #457 |
| checker | #459 |
| oct study | #460 |
| greatest improvements | #461 |
| distance visual | #461 |
| test evaluation | #462 |
| keratoplasty penetrating | #462 |
| hel | #466 |
| unpaired ttest | #467 |
| fibroblasts tgf | #467 |
| study pcr | #468 |
| examination diagnosis | #469 |
| background atopic | #469 |
| major sources | #470 |
| markers severity | #473 |
| allergy adult | #473 |
| metry | #475 |
| diagnosis rate | #476 |
| hladr expression | #476 |
| 13 mmhg | #478 |
| pollen seasons | #478 |
| fibroblasts primary | #478 |
| newly formed vessels | #480 |
| height measurement | #480 |
| reduce clinical | #480 |
| subjects eyes | #481 |
| interleukin 13 | #482 |
| examined prospective | #482 |
| crystalline lens implantation | #485 |
| accommodating | #488 |
| 21 eyes | #488 |
| induced 15 | #489 |
| shortterm study | #490 |
| myopia photorefractive | #490 |
| disodium cromoglycate | #493 |
| acuity intraocular | #495 |
| prolonged inflammation | #495 |
| ebv reactivation | #495 |
| months eyes | #498 |
| corneal | #498 |
| stain positive | #499 |
| exposure diesel | #499 |
| il2 tumor | #499 |
| silicone hydrogel | #500 |
| lens iol | #500 |
| symptoms efficacy | #501 |
| infections viral | #501 |
| pge2 cox2 | #502 |
| studies status | #502 |
| treatment eye | #502 |
| heidelberg retina | #503 |
| 42 eyes | #504 |
| eye position | #505 |
| 2 daily | #505 |
| airborne particulate matter | #506 |
| inflammatory status | #506 |
| correlate severity | #506 |
| penetrating male | #507 |
| aldose reductase | #509 |
| induced ocular | #509 |
| 1 mild | #511 |
| cats child | #512 |
| treatment visual | #514 |
| 45 subjects | #516 |
| topical | #516 |
| disposable equipment | #517 |
| inhibition production | #519 |
| observed baseline | #519 |
| male water | #519 |
| groups duration | #520 |
| lipopeptides lipoproteins | #520 |
| chemoattractant receptor | #522 |
| 01 | #522 |
| metaregression analysis | #523 |
| 10 normal volunteers | #524 |
| infection rsv | #524 |
| dinoprostone epithelial | #525 |
| studies trabeculectomy | #525 |
| studies cornea | #527 |
| trabeculectomy | #527 |
| density basal | #528 |
| giemsa staining | #528 |
| rhodanine | #531 |
| itchy | #531 |
| serum antigen | #535 |
| ocular symptoms | #535 |
| 44yearold | #536 |
| purpose case | #537 |
| patients cataract | #538 |
| total hydrocarbons | #538 |
| dependent migration | #539 |
| sac | #539 |
| placebo tablets | #540 |
| capsular bag | #540 |
| 80 anterior | #541 |
| visit 6 | #541 |
| administration topical | #542 |
| cases flow | #542 |
| 20 normal | #543 |
| infrared radiation | #543 |
| 6 male | #544 |
| ebv nuclear antigen | #546 |
| production cultured | #546 |
| time improved | #547 |
| periodic acid | #549 |
| pollution allergens | #549 |
| prospective comparative study | #550 |
| film layer | #550 |
| cryptomeria | #552 |
| il‐4 | #552 |
| effects cooling | #553 |
| disease complicated | #553 |
| engorgement | #554 |
| disease ded | #555 |
| genechip | #555 |
| fibroblasts response | #555 |
| setting department | #556 |
| noninfected cells | #557 |
| transplantation combined | #558 |
| density assessed | #558 |
| diesel exhaust particles | #559 |
| methods thirty | #559 |
| ocular infections | #560 |
| eyes iop | #560 |
| differentiation inflammatory | #560 |
| eyes 24 | #562 |
| laser trabeculoplasty | #562 |
| positive 30 | #563 |
| 16 age | #569 |
| count corneal | #569 |
| cultured corneal | #570 |
| levels il4 | #570 |
| meibomian | #572 |
| female humans specificity | #576 |
| allergen challenge | #577 |
| corneal diseases | #578 |
| iop eyes | #580 |
| 4 mrna | #580 |
| apparatus male | #582 |
| fibrosis fluorescent | #582 |
| lesions normal | #582 |
| increase vegf | #584 |
| department ophthalmology | #584 |
| tnfalpha stimulation | #584 |
| symptoms scores | #588 |
| female humans allergic | #589 |
| corneal epithelium | #589 |
| induced 4 | #589 |
| intraocular male | #589 |
| hladr antigen | #589 |
| patients csa | #589 |
| study lipid | #590 |
| diseases regulation | #591 |
| icam1 vcam1 | #592 |
| cytological techniques | #593 |
| observed real | #595 |
| findings evaluated | #597 |
| assay eye | #597 |
| epithelium corneal | #598 |
| cells chemokine | #599 |
| diesel exhaust | #602 |
| cornea epithelium | #603 |
| mrna tgf | #604 |
| thermometer | #605 |
| grading scale | #606 |
| inflammation status | #609 |
| topical adult | #609 |
| corneal nerves | #611 |
| thermography | #611 |
| eosinophils epithelial | #612 |
| fluorescent dyes humans | #613 |
| synergic | #614 |
| patients complained | #615 |
| antagonists humans | #615 |
| diagnosis type | #616 |
| cells oligopeptides | #616 |
| grades 0 | #617 |
| ocular allergy | #617 |
| flaps suture | #618 |
| subjects conclusion | #621 |
| il4 | #623 |
| lamp examination | #625 |
| years studied | #625 |
| glaucoma medications | #625 |
| ophthalmologists | #626 |
| occlusion treatment | #628 |
| micafungin | #635 |
| corneal haze | #636 |
| burning sensation | #636 |
| redness | #636 |
| patients tacrolimus | #636 |
| total immunoglobulin | #638 |
| contact lenses | #639 |
| eosinophils | #639 |
| based severity | #639 |
| male rhinitis | #640 |
| 511 patients | #640 |
| development allergic | #641 |
| 11 eyes | #641 |
| months 01 | #643 |
| performed modified | #643 |
| symptoms signs | #643 |
| observed follow | #644 |
| fibrosis actins | #645 |
| mellitus double | #645 |
| patients healthy volunteers | #650 |
| expression administration | #651 |
| viscosupplements | #651 |
| 2 females | #651 |
| eosinophils flow | #654 |
| analysis existence | #654 |
| diseases methods | #656 |
| comfortable | #657 |
| lacrimal | #657 |
| patients elisa | #660 |
| nerve density | #661 |
| 96well plate | #661 |
| chamber technique | #662 |
| treatment 0001 | #664 |
| lens wearers | #664 |
| acuity measured | #665 |
| molecule1 cell | #668 |
| viruses acute | #669 |
| damage scores | #669 |
| 10 age | #669 |
| cedar | #672 |
| stimulation rna | #672 |
| humans lacrimal | #673 |
| 11 males | #673 |
| scleritis | #677 |
| levels correlation | #678 |
| administration ophthalmic | #680 |
| adherence anti | #681 |
| test methods | #681 |
| antibody negative | #682 |
| chemokine gene | #683 |
| stainings | #684 |
| fibronectin cell | #684 |
| single visit | #685 |
| goblet | #686 |
| cells collected | #688 |
| differential diagnosis patients | #689 |
| visual acuity patients | #690 |
| atopic female humans | #694 |
| cells eye | #694 |
| 1 test | #695 |
| early antigen | #697 |
| inhibition expression | #697 |
| cromolyn | #700 |
| objective assessments | #700 |
| levels detection | #700 |
| intraocular inflammation | #703 |
| eyelid | #704 |
| labeling surface | #705 |
| antineoplastic child | #707 |
| participants eyes | #709 |
| pain baseline | #711 |
| allergens child | #712 |
| 1 month | #715 |
| fibroblasts flow | #715 |
| major characteristic | #717 |
| key cells | #718 |
| 5 eyes | #718 |
| dibenzazepines | #719 |
| preventing recurrence | #721 |
| production vascular | #722 |
| 088 ± | #724 |
| 32 eyes | #724 |
| promising treatment strategy | #725 |
| squamous metaplasia | #729 |
| followup treatment | #730 |
| 11 male | #730 |
| aged ophthalmology | #730 |
| cytology patients | #731 |
| eyes underwent | #733 |
| pollution data | #735 |
| suppressive effects | #736 |
| symptoms 5 | #737 |
| reductase inhibitor | #737 |
| intraocular lens | #740 |
| density compared | #741 |
| keratectomy | #741 |
| expression real | #744 |
| definition classification | #746 |
| blood eosinophils | #746 |
| unpaired test | #746 |
| inflammation lipid | #748 |
| purpose hypothesis | #749 |
| daily weather | #751 |
| cornea corneal | #751 |
| interleukin13 male | #752 |
| fibroblasts cultured | #754 |
| eyes 6 | #758 |
| iol implantation | #759 |
| follow cases | #759 |
| allergens anti | #762 |
| topical aged | #763 |
| intraocular lens implantation | #763 |
| trabeculectomy treatment | #763 |
| 148 years | #764 |
| drugs primary | #765 |
| aged chemokine | #766 |
| pathogenesis severe | #769 |
| oligopeptides rna | #769 |
| measurements improved | #772 |
| pge2 production | #775 |
| eotaxin | #776 |
| cells adolescent | #782 |
| role allergic | #783 |
| levels prostaglandin | #783 |
| limbus corneae | #784 |
| fluorescein fluoresceins | #784 |
| blinking | #785 |
| purpose analyze | #785 |
| treatment 1 | #785 |
| elevated levels | #789 |
| allergic disease | #790 |
| lenses intraocular | #792 |
| eyes normal | #792 |
| increased epithelial | #793 |
| techniques laminin | #793 |
| tacrolimus | #793 |
| ocular inflammation | #794 |
| 4 hne | #794 |
| months visual | #798 |
| treatment p0001 | #800 |
| report efficacy | #801 |
| positive linear | #801 |
| radioallergosorbent | #802 |
| excimer male | #804 |
| cells western | #806 |
| mucin | #813 |
| receptors ccr3 | #813 |
| 21 individuals | #814 |
| brush | #816 |
| acuity adolescent | #817 |
| biomicroscopy | #819 |
| concentration dose | #820 |
| aged cell | #820 |
| cells eosinophils | #821 |
| interleukin4 | #821 |
| phenotype practice | #822 |
| temperature case | #825 |
| year adolescent | #831 |
| preoperative level | #834 |
| lymphocytes compared | #834 |
| surgical outcome | #835 |
| cases follow | #835 |
| pachymetry | #840 |
| patients operation | #841 |
| individuals patients | #841 |
| implantation intraocular | #842 |
| ocular adolescent | #843 |
| symptoms improved | #843 |
| elevated iop | #845 |
| new surgical technique | #845 |
| exhaust | #848 |
| levels air | #848 |
| 2 weeks treatment | #848 |
| loss insensible | #851 |
| fluorescein | #853 |
| cell area | #855 |
| purpose prospectively | #855 |
| 10 eyes | #858 |
| methane hydrocarbons | #860 |
| myopic eyes | #861 |
| inhibitors diclofenac | #861 |
| histamine h1 | #865 |
| thiazolidines | #865 |
| thirteen cases | #866 |
| patients ocular | #867 |
| test kits | #868 |
| serum antibody titers | #872 |
| patients eyes | #874 |
| 01 compared | #874 |
| dry eyes | #876 |
| mitomycinc | #878 |
| syndrome sjs | #879 |
| evaluation early | #880 |
| h1 antagonists | #880 |
| benzamidine | #880 |
| patient comfort | #881 |
| assessing efficacy | #882 |
| cells contributes | #882 |
| diseases background | #883 |
| study eye | #886 |
| bleb | #887 |
| patients condition | #887 |
| specular | #890 |
| respiratory syncytial | #894 |
| 114 years | #894 |
| age eye | #895 |
| noncomparative | #897 |
| pain inflammation | #901 |
| ocular | #902 |
| levels pm25 | #903 |
| 20 eyes | #904 |
| benzophenones | #905 |
| decreased baseline | #905 |
| circulating autoantibodies | #907 |
| clinical signs | #910 |
| lacrimal duct | #911 |
| examined pcr | #911 |
| aureus young | #912 |
| gauze | #917 |
| corneae | #919 |
| sjögren | #920 |
| immunoglobulin immunosuppressive | #921 |
| 10 females | #925 |
| treatment symptoms | #928 |
| 8 males | #928 |
| immunoregulatory effects | #929 |
| epithelial lesions | #929 |
| histopathologic analysis | #930 |
| disease efficacy | #932 |
| normal controls | #933 |
| ophthalmologic surgical | #933 |
| beta1 tumor | #937 |
| epithelialization | #937 |
| iop measured | #939 |
| treatment severe | #940 |
| cytokines epithelial | #941 |
| symptoms evaluated | #941 |
| normal 1 | #943 |
| factor production | #946 |
| humans muscarinic | #946 |
| wheal | #947 |
| radioallergosorbent test | #949 |
| mgd | #949 |
| humans lenses | #950 |
| seasons young | #950 |
| ulcer humans | #952 |
| sensitivity values | #953 |
| 2 moderate | #957 |
| scanning confocal | #957 |
| aldose | #959 |
| singleagent therapy | #959 |
| 3 eyes | #959 |
| endpoint baseline | #960 |
| intracellular infection | #961 |
| sedating | #961 |
| expression 8 | #962 |
| dust mites | #963 |
| observed 3 | #965 |
| eyes 12 | #966 |
| ecp | #967 |
| total score | #968 |
| expression chemokine | #969 |
| positively stained | #971 |
| basal epithelial | #973 |
| term therapeutic | #973 |
| mcp1 gene | #980 |
| day month | #981 |
| 6 males | #983 |
| detected patients | #985 |
| ointment | #989 |
| 4 regulation | #990 |
| primary cultured | #992 |
| carried patients | #993 |
| observed conclusions | #994 |
| tenon | #994 |
| technique 2 | #998 |
| adult cornea | #1001 |
| observed vivo | #1002 |
| methods sixteen | #1002 |
| serum ige | #1005 |
| pediatric subjects | #1008 |
| accommodation ocular | #1009 |
| boyden | #1011 |
| time year | #1012 |
| eye infections | #1012 |
| piperidines pyridines | #1013 |
| allergic diseases | #1014 |
| 1 2 weeks | #1017 |
| blink | #1017 |
| normal volunteers | #1019 |
| impression | #1019 |
| improved 1 | #1020 |
| cells positively | #1021 |
| ω3 fatty acids | #1024 |
| model allergic | #1028 |
| studied prospectively | #1029 |
| induced chemotaxis | #1031 |
| diopter | #1032 |
| improved 3 | #1033 |
| 2 eyes | #1036 |
| 045 ± | #1040 |
| patching | #1040 |
| webbased questionnaire | #1040 |
| chemotaxis | #1042 |
| values analysis | #1043 |
| lysine 4 | #1044 |
| cells fibroblasts | #1044 |
| treatment skin | #1045 |
| concomitantly | #1045 |
| xerophthalmia | #1046 |
| indirect humans | #1050 |
| recurrence 6 | #1050 |
| allergen extracts | #1053 |
| symptoms score | #1054 |
| johnson syndrome | #1057 |
| eyelids | #1059 |
| study therapeutic | #1060 |
| allograft transplantation | #1062 |
| guidelines clinical | #1064 |
| giemsa | #1065 |
| staphylococcal enterotoxin | #1067 |
| pollution risk | #1067 |
| disposable | #1067 |
| noninfectious | #1070 |
| acuity patients | #1071 |
| goblet cell | #1071 |
| immunocytochemical study | #1073 |
| effective treating | #1075 |
| months corrected | #1075 |
| eyes received | #1076 |
| efficacy treatment | #1077 |
| benzamidines | #1079 |
| techniques ophthalmological | #1080 |
| syncytial virus | #1080 |
| ade | #1080 |
| allergic inflammatory | #1082 |
| expression icam1 | #1082 |
| sex matched | #1088 |
| cyclosporine patients | #1091 |
| ige anti | #1098 |
| corrected visual acuity | #1099 |
| assessed vivo | #1104 |
| diseases objective | #1104 |
| endothelium corneal | #1107 |
| 10 males | #1109 |
| meibomian glands | #1110 |
| rose | #1116 |
| lens capsule | #1116 |
| 30 patients | #1118 |
| keratopathy | #1121 |
| drops | #1121 |
| popularization | #1122 |
| 92 years | #1122 |
| periostin | #1125 |
| epithelium female | #1132 |
| clinical findings | #1133 |
| treatment objective | #1133 |
| assay fibroblasts | #1133 |
| cultures human | #1133 |
| anti icam1 | #1134 |
| evaluate therapeutic | #1136 |
| controls examined | #1137 |
| visual acuities | #1140 |
| healthy eyes | #1140 |
| prospective controlled | #1141 |
| small incision | #1143 |
| p0035 | #1146 |
| 4 daily | #1146 |
| minimum angle | #1149 |
| aphakic | #1150 |
| aged phacoemulsification | #1153 |
| cyclosporine humans | #1154 |
| interventional case | #1157 |
| airborne particulate | #1165 |
| sjögrens syndrome | #1171 |
| purpose evaluate | #1171 |
| cornea | #1173 |
| glands sjogren | #1173 |
| ophthalmological female | #1189 |
| fibronectins fibrosis | #1189 |
| immune mechanisms | #1189 |
| adult dermatitis | #1191 |
| levels chemokines | #1191 |
| spatial temporal resolution | #1193 |
| cytokine mrna | #1195 |
| refractory standard | #1207 |
| ded | #1209 |
| 84 ± | #1210 |
| concentrations alpha | #1210 |
| 18 females | #1211 |
| boyden chamber | #1212 |
| lasers excimer | #1215 |
| bengal | #1217 |
| scl | #1219 |
| stevens johnson | #1220 |
| par2 | #1222 |
| 025 | #1223 |
| mmc | #1230 |
| microscopy confocal | #1231 |
| allergic inflammation | #1233 |
| instilled | #1235 |
| correlation clinical | #1240 |
| wearers | #1241 |
| eyes treated | #1242 |
| muc5ac expression | #1249 |
| supply adult | #1254 |
| molecule expressed | #1265 |
| messenger reverse | #1266 |
| levels pge2 | #1270 |
| tomograph | #1271 |
| 4 normal | #1274 |
| period clinical | #1275 |
| anesthesia local | #1278 |
| aged substance | #1286 |
| study eyes | #1286 |
| 169 ± | #1287 |
| lacrimal apparatus | #1288 |
| dermatitis atopic | #1289 |
| phacoemulsification | #1290 |
| iol | #1294 |
| cac | #1300 |
| adult antibiotics | #1301 |
| controls 005 | #1302 |
| dryness | #1303 |
| photorefractive | #1304 |
| spring autumn | #1307 |
| intraocular lenses | #1308 |
| japanese cedar | #1310 |
| thermometry | #1311 |
| allergic | #1314 |
| chemokines chemotaxis | #1316 |
| higher severe | #1316 |
| corneal humans | #1317 |
| presence increased | #1318 |
| child chromatography | #1321 |
| expressed secreted | #1321 |
| ccl11 | #1322 |
| 830 | #1322 |
| membrane increased | #1331 |
| treatment improvements | #1334 |
| prostaglandin production | #1335 |
| light lipid | #1337 |
| ccr3 receptors | #1340 |
| fivepoint scale | #1341 |
| operation patients | #1343 |
| ped | #1348 |
| treatment 14 | #1353 |
| antigen child | #1360 |
| benzalkonium | #1365 |
| responses peripheral | #1371 |
| cytokines dinoprostone | #1374 |
| atopic diseases | #1377 |
| 00001 lower | #1383 |
| timeseries analysis | #1384 |
| ointments | #1396 |
| female glucocorticoids | #1399 |
| 18 eyes | #1399 |
| respiratory pathogen | #1404 |
| epithelial barrier function | #1407 |
| diseases diagnosis | #1413 |
| proteaseactivated receptor | #1413 |
| adult allergens | #1414 |
| normal adults | #1416 |
| 005 1 | #1419 |
| 1 week | #1425 |
| prospective comparative | #1428 |
| higher contrast | #1431 |
| patients cgvhd | #1432 |
| rast | #1434 |
| factors seasons | #1439 |
| corneal neovascularization | #1444 |
| haze | #1444 |
| temperature cell | #1445 |
| reduced 1 | #1451 |
| goblet cells | #1451 |
| macular oedema | #1453 |
| histocytological | #1458 |
| corneal opacity | #1465 |
| lens implantation | #1469 |
| complained | #1470 |
| production il4 | #1481 |
| outcome administration | #1488 |
| corneal edema | #1489 |
| data daily | #1497 |
| 2 minutes | #1498 |
| western cells | #1499 |
| detected frequently | #1499 |
| male metaplasia | #1500 |
| studies suture | #1502 |
| bulbar | #1502 |
| pgd2 | #1505 |
| human corneal | #1507 |
| ophthalmological | #1510 |
| female fluorescein | #1514 |
| staining | #1514 |
| 40 mmhg | #1522 |
| studies glaucoma | #1524 |
| total scores | #1526 |
| eosinophils female | #1527 |
| acuity adult | #1530 |
| inhibitors child | #1533 |
| cells density | #1537 |
| 7 females | #1541 |
| production primary | #1542 |
| cytometric analysis | #1544 |
| dioxide particulate | #1548 |
| virus rsv | #1553 |
| pollen rhinitis | #1559 |
| decreased treatment | #1560 |
| steroidal cell | #1566 |
| aged allergens | #1571 |
| fibronectin laminin | #1573 |
| cells 001 | #1575 |
| 15 females | #1580 |
| purpose investigate | #1581 |
| fibroblasts | #1583 |
| effective long | #1589 |
| assessed quantitative | #1591 |
| aldehyde reductase | #1597 |
| preservative | #1602 |
| ortho aminobenzoates | #1602 |
| cells 0001 | #1603 |
| humans intraocular | #1624 |
| vdt | #1624 |
| incidence adverse events | #1625 |
| weeks administration | #1629 |
| eye | #1630 |
| cyclosporine female | #1637 |
| epstein‐barr virus | #1638 |
| epsteinbarr virus ebv | #1641 |
| mitomycin mmc | #1643 |
| preschool dermatitis | #1644 |
| capsule crystalline | #1654 |
| subjects examined | #1658 |
| prevalence severe | #1662 |
| 10 healthy controls | #1663 |
| syncytial | #1663 |
| reaction young | #1665 |
| damage patients | #1666 |
| function small | #1670 |
| infections fungal | #1673 |
| higher normal | #1674 |
| 2 cytokine | #1685 |
| pm25 levels | #1686 |
| dose equivalent | #1687 |
| confocal middle | #1698 |
| 7 males | #1711 |
| outcome visual | #1713 |
| disease defined | #1713 |
| subjects adolescent | #1716 |
| whitney test | #1721 |
| 744 | #1725 |
| topical application | #1735 |
| cytology | #1741 |
| central corneal | #1741 |
| treatment short | #1742 |
| severity treatment | #1754 |
| years 19 | #1754 |
| antigen anti | #1756 |
| iols | #1760 |
| rsv infection | #1761 |
| eightysix patients | #1764 |
| oral steroids | #1775 |
| inflammation assessed | #1779 |
| enterotoxins female | #1789 |
| alpha sma | #1798 |
| mild cases | #1802 |
| 10 healthy | #1811 |
| endophthalmitis eye | #1815 |
| punctate | #1817 |
| antifungal treatment | #1821 |
| japan methods | #1823 |
| receptor par2 | #1823 |
| regulated activation | #1825 |
| sjs | #1827 |
| eosinophil | #1828 |
| 15 minutes | #1828 |
| child dermatitis | #1832 |
| mediator release | #1835 |
| epithelial damage | #1835 |
| factor tnfalpha | #1836 |
| fibroblasts normal | #1837 |
| corneal transplantation | #1838 |
| degrees 4 | #1839 |
| eye examination | #1840 |
| prostaglandin receptors | #1841 |
| inflammation injections | #1842 |
| month 3 | #1846 |
| effects aged | #1848 |
| receptors prostaglandin | #1853 |
| ulcer female | #1857 |
| 005 differences | #1858 |
| comparative evaluation | #1860 |
| shield | #1860 |
| ari | #1862 |
| tnfalpha production | #1862 |
| humans immunosuppressive | #1874 |
| surgery purpose | #1890 |
| cataract surgery | #1893 |
| aphakia | #1893 |
| ige production | #1900 |
| cells epithelial | #1909 |
| sterilized | #1912 |
| interleukin 4 | #1920 |
| ihc staining | #1923 |
| mast cell degranulation | #1929 |
| contact female | #1935 |
| contribute pathogenesis | #1942 |
| 013 ± | #1943 |
| severe persistent | #1946 |
| protein female | #1946 |
| patients exhibited | #1947 |
| score clinical | #1961 |
| vcam1 expression | #1962 |
| 9 males | #1970 |
| 5 minutes | #1970 |
| 4 males | #1971 |
| comfort | #1972 |
| device treatment | #1972 |
| corrected visual | #1974 |
| gpc | #1974 |
| month 1 | #1975 |
| intraocular | #1977 |
| nonuse | #1979 |
| eyes | #1980 |
| controls p005 | #1984 |
| females age | #1990 |
| studies cell | #1992 |
| irritation | #1994 |
| bak | #1999 |
| reaction serine | #2013 |
| diseases diagnostic | #2014 |
| erosions | #2016 |
| tacrolimus adult | #2023 |
| agents male | #2023 |
| surgery 1 | #2025 |
| ccl5 chemokines | #2026 |
| chemotaxis leukocyte | #2031 |
| increased vegf | #2036 |
| treated eyes | #2038 |
| coherence treatment | #2038 |
| based incidence | #2048 |
| eye female | #2049 |
| corneal topography | #2066 |
| allergens animals | #2067 |
| versus normal | #2067 |
| ambient air pollution | #2067 |
| pollen | #2068 |
| dexamethasone enzyme | #2073 |
| herpetic | #2075 |
| temperature measured | #2078 |
| cytokines enzyme | #2084 |
| ophthalmologic | #2091 |
| cytokines dose | #2093 |
| therapeutic effects | #2106 |
| aged antifungal | #2107 |
| activation normal | #2108 |
| clinical examinations | #2112 |
| cultured chemokine | #2118 |
| average concentrations | #2119 |
| acd | #2127 |
| reaction statistics | #2128 |
| human α | #2132 |
| endopeptidases serine | #2137 |
| docosahexaenoic acid | #2137 |
| mucin2 | #2140 |
| antibody positive | #2142 |
| vegf production | #2143 |
| incidence adverse | #2148 |
| scored | #2157 |
| controls 0001 | #2158 |
| expression patient | #2160 |
| umin | #2163 |
| production inhibited | #2164 |
| curve reproducibility | #2164 |
| virus human | #2170 |
| study flow | #2171 |
| density lower | #2174 |
| pressure iop | #2177 |
| sensation | #2181 |
| dyes humans | #2183 |
| adult administration | #2184 |
| regulation adolescent | #2185 |
| eyes patients | #2186 |
| eye disease | #2190 |
| child computer | #2191 |
| aged mitomycin | #2192 |
| diseases female | #2192 |
| duct obstruction | #2202 |
| pseudophakic | #2208 |
| ulcer patients | #2219 |
| cases severe | #2231 |
| greater concentrations | #2232 |
| 1 3 months | #2234 |
| immunoglobulin male | #2235 |
| upper lower | #2236 |
| matter pm25 | #2243 |
| rater agreement | #2246 |
| vital | #2246 |
| pollens | #2247 |
| scores correlated | #2247 |
| allergic seasonal | #2250 |
| groups difference | #2250 |
| tryptases | #2264 |
| compared vehicle | #2265 |
| individuals adolescent | #2270 |
| myopic | #2271 |
| slit | #2275 |
| il4 il13 | #2279 |
| exposure particulate | #2280 |
| uncorrected | #2284 |
| studies stem | #2285 |
| 6 months | #2290 |
| diseases enzyme | #2294 |
| cooling | #2297 |
| female gels | #2302 |
| humans hypersensitivity | #2311 |
| clinical appearance | #2312 |
| topical treatment | #2312 |
| rsv | #2316 |
| performed treatment | #2323 |
| animal study | #2332 |
| hours dose | #2336 |
| il4 production | #2339 |
| culture supernatants | #2343 |
| weeks 1 | #2344 |
| mann whitney | #2351 |
| ca125 antigen | #2354 |
| method assessing | #2371 |
| syncytial viruses | #2377 |
| skin adolescent | #2378 |
| treatment 2 | #2392 |
| immunosuppressive agents | #2409 |
| relieving | #2410 |
| months initiation | #2412 |
| aged nitrogen | #2415 |
| ophthalmology | #2415 |
| child enzyme | #2420 |
| stevens | #2422 |
| effective patients | #2424 |
| intraocular pressure | #2425 |
| prostaglandin | #2433 |
| interleukin2 receptors | #2456 |
| transcription levels | #2459 |
| sclera | #2464 |
| glaucoma humans | #2492 |
| ige antibody | #2493 |
| enteric coated | #2498 |
| fungal female | #2498 |
| diseases adolescent | #2503 |
| scores clinical | #2510 |
| obstruction male | #2513 |
| histamine | #2514 |
| h1 receptor | #2516 |
| histamine humans | #2533 |
| humans hyperemia | #2535 |
| levels alpha | #2543 |
| ebv | #2546 |
| patients symptoms | #2550 |
| cell expressed | #2557 |
| correlated severity | #2565 |
| oct | #2571 |
| methods clinical | #2571 |
| flare | #2573 |
| male polymerase | #2573 |
| controls serum | #2578 |
| penetrating | #2579 |
| mannwhitney | #2580 |
| vcam1 | #2583 |
| tonometry ocular | #2587 |
| aged myopia | #2593 |
| excimer laser | #2597 |
| methods subjects | #2602 |
| fibroblasts humans | #2610 |
| subjects 12 | #2614 |
| complications adolescent | #2619 |
| baseline treatment | #2620 |
| contact lens | #2624 |
| postsurgical | #2629 |
| eosinophilia female | #2629 |
| 6 months treatment | #2638 |
| lamp | #2646 |
| cyclosporine drug | #2647 |
| cyclosporine csa | #2653 |
| alpha adolescent | #2655 |
| 412 | #2656 |
| administered day | #2664 |
| rantes | #2665 |
| mucins | #2672 |
| cataract extraction | #2683 |
| symptom score | #2687 |
| infections respiratory | #2694 |
| groups differences | #2695 |
| bf | #2698 |
| tearing | #2698 |
| chemokine ccl5 | #2712 |
| studies glucocorticoids | #2717 |
| control eyes | #2721 |
| muc1 | #2726 |
| fibroblasts gene | #2731 |
| alpha vascular | #2735 |
| chemokine production | #2739 |
| hne | #2743 |
| factors chemotaxis | #2746 |
| laser scanning | #2747 |
| tomography oct | #2754 |
| immunocytochemical staining | #2759 |
| betamethasone | #2761 |
| matched normal | #2772 |
| total ige | #2772 |
| atopic female | #2773 |
| chronic graft | #2786 |
| humans immunoenzyme | #2792 |
| symptomatic improvement | #2794 |
| prevention adolescent | #2797 |
| male adolescent | #2813 |
| iop | #2817 |
| scores lower | #2818 |
| whitney | #2819 |
| atopic dermatitis | #2821 |
| higher cases | #2821 |
| dry | #2840 |
| groups normal | #2842 |
| analog scale | #2845 |
| aminobenzoates | #2846 |
| months surgery | #2850 |
| crystalline lens | #2855 |
| treatment 4 | #2868 |
| fibroblasts fibronectins | #2889 |
| qol scores | #2892 |
| syndrome patients | #2902 |
| evaporation rate | #2903 |
| mannwhitney test | #2905 |
| test performed | #2907 |
| anterior chamber | #2907 |
| il1beta | #2910 |
| tests diagnosis | #2922 |
| postoperative follow | #2926 |
| drop | #2927 |
| cgvhd | #2929 |
| surgery 2 | #2932 |
| eye diseases | #2940 |
| interleukin8 il8 | #2953 |
| endophthalmitis | #2955 |
| refraction ocular | #2961 |
| excision | #2987 |
| inter rater | #3000 |
| eosinophils humans | #3014 |
| measured elisa | #3014 |
| normal eyes | #3037 |
| cultured chemokines | #3051 |
| agents interferon | #3054 |
| protease activated | #3059 |
| staining labeling | #3068 |
| safety assessed | #3072 |
| evaporation | #3080 |
| aged anti | #3083 |
| treatment total | #3085 |
| immunologic receptors | #3118 |
| baseline month | #3124 |
| rtpcr | #3132 |
| expression adhesion | #3132 |
| dermatitis | #3150 |
| vehicle | #3153 |
| cells graft | #3163 |
| susceptibility humans | #3175 |
| cell count | #3181 |
| symptom scores | #3181 |
| methods seventy | #3188 |
| 10 patients | #3190 |
| investigate efficacy | #3197 |
| recruited study | #3208 |
| sjogren syndrome | #3228 |
| study medication | #3240 |
| patient global | #3249 |
| cell densities | #3269 |
| accommodation | #3274 |
| acuity | #3280 |
| meniscus | #3289 |
| variance case | #3295 |
| interferometry | #3299 |
| normal control subjects | #3302 |
| intraoperative male | #3322 |
| allergens | #3325 |
| cells assessed | #3332 |
| subjective | #3340 |
| efficacy anti | #3343 |
| diclofenac sodium | #3345 |
| dressings | #3352 |
| histamine receptor | #3356 |
| cellular level | #3367 |
| pfu | #3369 |
| diabetic patients | #3375 |
| fibroblast proliferation | #3377 |
| coherence tomography | #3398 |
| ova | #3409 |
| instillation | #3411 |
| normal subjects | #3415 |
| air pollutants | #3416 |
| alpha cell | #3440 |
| patients obstructive | #3460 |
| host disease humans | #3469 |
| papilla | #3493 |
| cataract | #3514 |
| local excision | #3555 |
| interleukin8 male | #3570 |
| visual analog | #3572 |
| agents steroidal | #3585 |
| sjogren | #3591 |
| tokyo | #3609 |
| immunoglobulin ige | #3614 |
| signs | #3617 |
| agents incidence | #3623 |
| plaque formation | #3626 |
| weeks surgery | #3640 |
| method enzyme | #3648 |
| pressure male | #3653 |
| cell density | #3654 |
| fiftytwo patients | #3661 |
| adult chronic | #3668 |
| vegf mrna | #3694 |
| disease adolescent | #3694 |
| 016 ± | #3698 |
| cytological | #3709 |
| 29 years | #3711 |
| gels humans | #3720 |
| week 1 | #3745 |
| suture techniques | #3751 |
| adult air | #3751 |
| signs symptoms | #3758 |
| pm25 | #3770 |
| situ nickend | #3772 |
| helper type | #3773 |
| management disease | #3773 |
| anterior segment | #3782 |
| hydrochloride | #3792 |
| lenses | #3815 |
| docosahexaenoic acid dha | #3823 |
| perennial | #3824 |
| patients examined | #3835 |
| amniotic | #3843 |
| studies severity | #3851 |
| intercellular adhesion molecule | #3865 |
| interleukin13 | #3866 |
| strabismus | #3900 |
| diseases study | #3906 |
| complications observed | #3914 |
| mann | #3916 |
| interleukin2 interleukin4 | #3949 |
| specific ige | #3951 |
| subjects included | #3968 |
| cell expression | #3989 |
| microscopy | #3992 |
| chemokines | #3992 |
| discontinued treatment | #3993 |
| break | #3994 |
| lower compared | #3996 |
| studies roc | #3998 |
| ulcer | #4009 |
| cells hla | #4035 |
| female flow | #4036 |
| echinocandins | #4040 |
| acrylic resins | #4047 |
| immunosuppressive | #4068 |
| readings | #4071 |
| steroid | #4091 |
| subjects methods | #4093 |
| steroid treatment | #4095 |
| acinar | #4097 |
| discontinue | #4100 |
| inflammatory disorders | #4103 |
| tended higher | #4106 |
| ige | #4116 |
| bronchial asthma | #4135 |
| th2 | #4137 |
| severe effects | #4168 |
| female glaucoma | #4179 |
| aged sensitivity | #4189 |
| α induced | #4193 |
| papillary | #4193 |
| male surveys | #4211 |
| measured enzyme | #4218 |
| percentages | #4223 |
| visual acuity | #4239 |
| gamma interleukin1 | #4281 |
| heidelberg | #4286 |
| adult antibody | #4327 |
| purpose report | #4328 |
| clinically diagnosed | #4349 |
| visual function | #4360 |
| edema | #4368 |
| effective improving | #4382 |
| 11 patients | #4410 |
| reaction rna | #4417 |
| infiltrates | #4459 |
| interleukin | #4482 |
| healed | #4489 |
| conclusions clinical | #4503 |
| studies environmental | #4513 |
| scores | #4515 |
| gamma interleukin4 | #4530 |
| 14 28 | #4549 |
| baseline 2 | #4575 |
| excimer | #4592 |
| viral respiratory | #4601 |
| surface reconstruction | #4608 |
| blinding | #4654 |
| years recruited | #4660 |
| lid | #4671 |
| cytometric | #4683 |
| studies prosthesis | #4704 |
| patients bilateral | #4711 |
| chemotactic | #4713 |
| treatment conclusions | #4714 |
| 4 9 | #4720 |
| tomography optical | #4729 |
| immunoenzyme | #4748 |
| dermatitis contact | #4754 |
| 36 years | #4755 |
| 80 child | #4790 |
| glaucoma patients | #4793 |
| purpose assess | #4807 |
| healthy control subjects | #4826 |
| patients administration | #4833 |
| 111 patients | #4837 |
| immunoenzyme techniques | #4857 |
| protein array | #4864 |
| allergy | #4868 |
| fluoresceins fluorescent | #4892 |
| adult biological | #4902 |
| chronic gvhd | #4913 |
| foreign body | #4922 |
| defensins | #4929 |
| infrared rays | #4946 |
| scale 0 | #4948 |
| logarithm | #4974 |
| lower density | #5019 |
| nitrogen dioxide | #5023 |
| months treatment | #5023 |
| optical coherence | #5029 |
| groups compared | #5036 |
| opacities | #5052 |
| enterotoxins | #5054 |
| safety treatment | #5056 |
| unpaired | #5095 |
| amnion | #5097 |
| induced male | #5101 |
| strip | #5103 |
| lipopeptides | #5119 |
| glaucoma | #5131 |
| purposewe | #5143 |
| receptors chemokine | #5174 |
| patients 100 | #5189 |
| steroids | #5194 |
| thirtysix patients | #5224 |
| epithelium | #5224 |
| observed 2 | #5246 |
| determine efficacy | #5268 |
| lysine male | #5269 |
| child combined | #5301 |
| analysis reverse | #5302 |
| 2 weeks | #5303 |
| enzyme linked | #5314 |
| time measurements | #5318 |
| 74 years | #5320 |
| humans hyperthermia | #5365 |
| imidazoles male | #5366 |
| 20 25 | #5367 |
| allergen | #5403 |
| metaplasia | #5404 |
| agents chronic | #5423 |
| factors visual | #5431 |
| procedures postoperative | #5475 |
| differential disease | #5487 |
| igg anti | #5508 |
| keratitis | #5509 |
| alum | #5527 |
| mucin1 | #5530 |
| treatment follow | #5537 |
| barr virus | #5547 |
| humans lasers | #5560 |
| epithelial barrier | #5584 |
| counted | #5606 |
| visual analog scale | #5621 |
| spearman correlation | #5634 |
| aims evaluate | #5656 |
| giant | #5659 |
| publication administration | #5662 |
| il13 | #5676 |
| sutures | #5684 |
| eye proteins | #5692 |
| opacity | #5697 |
| histamine antagonists | #5721 |
| tonometry | #5735 |
| techniques cells | #5746 |
| grades | #5747 |
| th2 cells | #5747 |
| adult cell | #5754 |
| 889 | #5801 |
| male time | #5839 |
| tgfbeta1 | #5853 |
| sickness impact | #5861 |
| icam1 | #5871 |
| agents candida | #5881 |
| score 3 | #5903 |
| biomarkers case | #5924 |
| expression alpha | #5963 |
| nsaid | #5969 |
| antibody anti | #5999 |
| microscopy study | #6002 |
| chemotactic factors | #6005 |
| ip10 | #6027 |
| adverse health effects | #6035 |
| rhinitis allergic | #6041 |
| humans hyaluronic | #6046 |
| higher compared | #6074 |
| exacerbate | #6114 |
| controlled clinical | #6123 |
| baseline 1 | #6145 |
| placebo treatment | #6146 |
| thickening | #6158 |
| male neutrophils | #6171 |
| patients refractory | #6181 |
| treatment adverse | #6199 |
| desiccation | #6204 |
| resultsthe | #6224 |
| genetic adolescent | #6226 |
| diagnostic techniques | #6234 |
| efficacy | #6247 |
| impact profile | #6258 |
| subjects randomized | #6267 |
| johnson | #6274 |
| steroidal | #6295 |
| cells lymphocytes | #6296 |
| patients control | #6337 |
| dosed | #6343 |
| allergies | #6348 |
| ocular hypertension | #6376 |
| 005 conclusion | #6428 |
| ulceration | #6435 |
| japan male | #6443 |
| asthmatic agents | #6445 |
| wearing | #6466 |
| 2 groups | #6475 |
| air pollution | #6514 |
| rejection humans | #6543 |
| house dust | #6543 |
| primary human | #6559 |
| diclofenac | #6566 |
| 3 groups | #6582 |
| anti asthmatic | #6611 |
| linked immunosorbent | #6618 |
| glucocorticoids humans | #6618 |
| 3 months | #6643 |
| conventional therapy | #6652 |
| immunosorbent assay | #6675 |
| months compared | #6704 |
| humans japan | #6704 |
| inflammatory | #6764 |
| chemokine | #6774 |
| graded | #6779 |
| breakup | #6780 |
| severe | #6799 |
| serum total | #6811 |
| 1 14 | #6842 |
| male microscopy | #6859 |
| treatment refractory | #6864 |
| bcva | #6877 |
| enzymelinked immunosorbent assay | #6904 |
| conventional treatment | #6981 |
| wear | #7013 |
| adhesion molecules | #7016 |
| years treated | #7049 |
| contrast sensitivity | #7060 |
| observed treatment | #7063 |
| humans hypothermia | #7079 |
| 6 patients | #7102 |
| epsteinbarr virus | #7188 |
| transplantation child | #7270 |
| patients 9 | #7284 |
| water loss | #7310 |
| infections herpesvirus | #7328 |
| viral female | #7329 |
| treatment period | #7342 |
| syndromes | #7375 |
| photography | #7394 |
| severity | #7473 |
| relief | #7481 |
| seasonal | #7483 |
| alpha regulation | #7520 |
| confocal microscopy | #7575 |
| epithelial | #7618 |
| humans immunoglobulin | #7674 |
| inflammatory agents | #7677 |
| autumn | #7680 |
| treatment decreased | #7714 |
| calcineurin inhibitors | #7727 |
| 16 patients | #7794 |
| hyperthermia induced | #7892 |
| cyclosporine | #7933 |
| epstein barr | #8024 |
| steroidal anti | #8072 |
| tnfalpha | #8140 |
| methods fifty | #8160 |
| fk506 | #8206 |
| aged minimally | #8301 |
| barr | #8314 |
| production human | #8367 |
| assess safety | #8419 |
| evaluate effectiveness | #8448 |
| purpose | #8455 |
| patients normal | #8497 |
| regulation vascular | #8551 |
| statistically differences | #8556 |
| hypothermia induced | #8648 |
| graft rejection | #8670 |
| hladr | #8682 |
| corticosteroid | #8683 |
| epithelial cells | #8827 |
| score 1 | #8860 |
| design prospective | #8861 |
| year male | #8873 |
| ceramides | #8893 |
| capsular | #8909 |
| ovalbumin | #8972 |
| silicone | #8991 |
| anti inflammatory | #9041 |
| surgical flaps | #9087 |
| 3 6 | #9098 |
| complaints | #9098 |
| illness adolescent | #9141 |
| immunosorbent | #9162 |
| humidity | #9176 |
| cutoff values | #9181 |
| patients 16 | #9191 |
| 4 12 | #9193 |
| treatment adolescent | #9195 |
| 0 3 | #9331 |
| wilcoxon | #9408 |
| 375 | #9414 |
| virus ebv | #9435 |
| 8 patients | #9463 |
| humans intraoperative | #9556 |
| hypersensitivity | #9569 |
| reaction tumor | #9638 |
| adult anti | #9709 |
| particulate matter | #9803 |
| superficial | #9826 |
| refraction | #9835 |
| methods prospective | #9836 |
| anesthetics local | #9840 |
| limbic | #9855 |
| fluorescent dyes | #9935 |
| term treatment | #10001 |
| objectively | #10055 |
| postoperatively | #10097 |
| technique indirect | #10132 |
| symptoms patients | #10143 |
| 1year followup | #10154 |
| 10 minutes | #10161 |
| foreign | #10171 |
| factor vegf | #10178 |
| biomarkers child | #10229 |
| antigens humans | #10284 |
| compared treatment | #10317 |
| rhinitis | #10337 |
| glands | #10364 |
| cytokines | #10378 |
| week 4 | #10414 |
| common complication | #10417 |
| questionnaire | #10420 |
| shortterm | #10427 |
| mast cells | #10496 |
| lens | #10588 |
| subjects age | #10599 |
| longterm treatment | #10644 |
| chamber | #10647 |
| male prospective | #10703 |
| volunteers | #10707 |
| substance | #10715 |
| compared controls | #10729 |
| nsaids | #10777 |
| cells th2 | #10778 |
| filtering | #10900 |
| metabolism male | #10953 |
| il5 | #11022 |
| examinations | #11187 |
| patient demographics | #11192 |
| 20 40 | #11212 |
| body temperature | #11219 |
| complications retrospective | #11251 |
| eczema | #11287 |
| patients 4 | #11337 |
| purposeto | #11381 |
| nonsteroidal | #11393 |
| corrected | #11394 |
| mast | #11549 |
| interleukin8 | #11599 |
| eosinophilic | #11723 |
| adjunctive | #11730 |
| receptors immunologic | #11956 |
| longterm outcomes | #12069 |
| evaluate | #12086 |
| grading | #12107 |
| coherence | #12125 |
| prospective | #12163 |
| 0001 conclusions | #12216 |
| csa | #12259 |
| asthmatic | #12282 |
| sickness | #12312 |
| tnf α | #12395 |
| thirty | #12576 |
| volunteers humans | #12586 |
| evaluate effects | #12612 |
| elisa | #12717 |
| mucous | #12766 |
| tnfα | #12781 |
| agents anti | #12822 |
| evaluate safety | #12879 |
| host disease | #12922 |
| seconds | #13199 |
| minutes | #13216 |
| complications diabetes | #13262 |
| epithelia | #13267 |
| 4 weeks | #13267 |
| 005 | #13326 |
| tests performed | #13356 |
| 1 3 | #13413 |
| 2 cases | #13447 |
| underwent | #13549 |
| western blot analysis | #13578 |
| prosthesis design | #13600 |
| cultured coculture | #13613 |
| particulate | #13632 |
| clinical examination | #13829 |
| life surveys | #13937 |
| mast cell | #13997 |
| study clinical | #14017 |
| dogs female | #14046 |
| graft host | #14084 |
| 60 patients | #14391 |
| myopia | #14577 |
| diseases diabetes | #14729 |
| vascular cell | #14846 |
| spearman | #14877 |
| implantation | #14889 |
| infections staphylococcus | #15065 |
| hyaluronic | #15111 |
| allograft | #15158 |
| patients follow | #15344 |
| visual | #15382 |
| refractory | #15389 |
| burning | #15485 |
| discontinued | #15495 |
| 1 2 | #15658 |
| longterm | #15717 |
| 006 | #15839 |
| graft | #15913 |
| tnf alpha | #16084 |
| radiation injuries | #16251 |
| patients divided | #16456 |
| 32 patients | #16659 |
| 15 patients | #16684 |
| adhesion molecule1 | #16940 |
| herpesvirus 4 | #16966 |
| evaluate efficacy | #17035 |
| 4 human | #17084 |
| patients assigned | #17274 |
| noninvasive | #17324 |
| molecule1 | #17435 |
| antibiotics antineoplastic | #17587 |
| histopathologic | #17743 |
| acid male | #17891 |
| method female | #17912 |
| anterior | #17986 |
| symptoms | #18008 |
| inflammation | #18029 |
| healthy | #18209 |
| morphologic | #18280 |
| stained | #18391 |
| alkylating | #18391 |
| vegf | #18469 |
| 0001 | #18534 |
| cold temperature | #18622 |
| 00001 | #18681 |
| 9 patients | #18689 |
| neovascularization | #19381 |
| female fluorescent | #19461 |
| stromal | #19499 |
| aged postoperative | #19510 |
| lipids male | #19666 |
| endothelial growth | #19723 |
| nerve fibers | #19872 |
| follow period | #19917 |
| artificial | #20012 |
| female graft | #20067 |
| 24 patients | #20143 |
| count cell | #20148 |
| epithelial cell | #20437 |
| complications prospective | #20558 |
| patients evaluated | #20800 |
| 22 patients | #21524 |
| 003 | #21648 |
| daily | #22391 |
| gland | #22647 |
| followup period | #22674 |
| male middle aged | #22802 |
| ifngamma | #23824 |
| outcome measures | #24510 |
| enrolled | #24838 |
| transplantation homologous | #25557 |
| patients adolescent | #25760 |
| adult body | #25783 |
| adult analysis | #26261 |
| conclusions patients | #26516 |
| adult biomarkers | #29382 |
| statistically | #29861 |
| age matched | #29948 |
| humans inflammation | #30660 |
| cells female | #31500 |
Jalankan laporan | |
Prominent publications by Hiroshi Fujishima
KOL-Index: 19369
PURPOSE: To describe MUC5AC alterations and the ocular surface disorder in atopic patients with or without corneal ulcers.
METHODS: Atopic patients' eyes were divided into two groups according to the presence and absence of corneal ulceration. The subjects underwent corneal sensitivity measurements, Schirmer test, tear film break-up time (BUT), fluorescein and Rose Bengal staining of the ocular surface and conjunctival impression cytology and brush cytology. Impression cytology samples ...
| Dikenal sebagai Ocular Surface | Eyes Corneal Ulcers | Atopic Patients | Brush Cytology | Akc Vkc |
Application of Visante Optical Coherence Tomography Tear Meniscus Height Measurement in the Diagnosis of Dry Eye Disease
[ PUBLICATION ]
PURPOSE: To investigate the applicability of tear meniscus height (TMH) measurement using Visante optical coherence tomography (OCT) in the diagnosis of dry eye disease.
DESIGN: Prospective, controlled, single-center study.
PARTICIPANTS: Twenty-four right eyes of 24 patients (6 males, 18 females; mean age, 63.14±13.4 years) with definite dry eye according to the Japanese dry eye diagnostic criteria and 27 right eyes of 27 control subjects (12 males, 15 females; mean age, 56.04±14.22 ...
| Dikenal sebagai Dry Eye Disease | Coherence Tomography | Tear Meniscus Height | Sensitivity Specificity | Strip Meniscometry |
Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease.
[ PUBLICATION ]
BACKGROUND: Although the oxidative stress status in atopic skin disease has been reported to be elevated, there are still no studies related to the status of oxidative stress in atopic ocular surface disease. The purpose of this study was to evaluate the ocular surface lipid oxidative stress status and inflammation in atopic keratoconjunctivitis (AKC) patients and normal subjects.
METHODS: Twenty eight eyes of 14 patients (9 males, 5 females) with AKC and 18 eyes of 9 age and sex matched ...
| Dikenal sebagai Oxidative Stress | Akc Patients | Surface Disease | Inflammatory Cells | 5 Females |
KOL-Index: 11411
PURPOSE: To evaluate the effectiveness and safety of a novel cyclosporine 0.1% aqueous ophthalmic solution in a large population with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC).
METHODS: A prospective observational postmarketing study was initiated in Japan. A total of 594 patients with VKC or AKC were started on this drug within 1 year after market launch (January 2006) and completed a 6-month follow-up. These patients were observed clinically, and ...
| Dikenal sebagai Vkc Akc | Allergic Conjunctivitis | Topical Steroids | 1 Month | Objective Signs |
Alterations of the ocular surface epithelial MUC16 and goblet cell MUC5AC in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface at cellular level in the conjunctiva and the cornea may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate the MUC16 and MUC5AC alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis (AKC).
METHODS: Thirty-six eyes of 18 AKC patients as well as 28 eyes of 14 age- and ...
| Dikenal sebagai Atopic Keratoconjunctivitis | Ocular Surface | Patients Akc | Muc5ac Muc16 | Goblet Cell |
KOL-Index: 10572
BACKGROUND: The pathogenesis of the ocular surface disease in atopic keratoconjunctivitis (AKC) and vernal keratoconjunctivitis (VKC) has not been fully understood. We tried to clarify the differences in the ocular surface status in patients with AKC, VKC, and healthy control subjects.
METHODS: Twenty-four eyes of 12 AKC patients, 12 eyes of six VKC patients, and 20 eyes of 10 normal control subjects were studied. The subjects underwent corneal sensitivity measurements, Schirmer test, ...
| Dikenal sebagai Ocular Surface | Atopic Keratoconjunctivitis | Patients Akc | Eyes Vkc | Brush Cytology |
Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis
[ PUBLICATION ]
BACKGROUND: An increased understanding of the ocular surface alterations at the cellular level in the conjunctiva and the cornea, may help explain the pathogenesis and the subsequent clinical appearance of atopic ocular allergies, which may be potentially blinding.
PURPOSE: To investigate MUC 1, 2 and 4 alterations, tear function and the ocular surface disorder in patients with atopic keratoconjunctivitis.
METHODS: Twenty-eight eyes of 14 atopic keratoconjunctivitis patients as well as ...
| Dikenal sebagai Atopic Keratoconjunctivitis | Ocular Surface | Brush Cytology | Corneal Sensitivity | Epithelial Mucins |
KOL-Index: 10372
PURPOSE: To prospectively assess the clinical outcome after implantation of the 1CU accommodating intraocular lens (IOL) and a foldable acrylic IOL (AcrySof, Alcon).
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa Hospital, Ichikawa, and Minami Aoyama Eye Clinics, Tokyo, Yokohama, Japan.
METHODS: Twenty-two eyes of 16 patients with cataract had phacoemulsification implantation of 1CU accommodating IOL. Twenty eyes of 10 age-matched and sex-matched patients with ...
| Dikenal sebagai Intraocular Lens | Visual Acuity | 1cu Iol | Cataract Surgery | Amplitude Accommodation |
KOL-Index: 10324
PURPOSE: Eosinophils are known to have important roles in the pathogenesis of allergic conjunctivitis. Prostaglandin (PG) D2, which has been implicated as a factor in allergic diseases, is known to have chemotactic activity for eosinophils. Its receptor, chemoattractant receptor homologous molecule expressed on TH2 (CRTH2), serves as a receptor for PGD2 and has been reported to mediate PGD2-dependent migration of eosinophils. In the present study, both eosinophil toxic activity for ...
| Dikenal sebagai Receptor Crth2 | Chemotaxis Eosinophils | Allergic Conjunctivitis | Pgd2dependent Migration | Homologous Molecule |
A Randomized, Placebo-Controlled Clinical Trial of Tacrolimus Ophthalmic Suspension 0.1% in Severe Allergic Conjunctivitis
[ PUBLICATION ]
AIMS: To examine the efficacy of tacrolimus ophthalmic suspension 0.1% in treating severe allergic conjunctivitis.
METHODS: This was a multicenter, randomized, double-masked, placebo-controlled clinical trial. Fifty-six patients with severe allergic conjunctivitis in whom topical antiallergic agents and corticosteroids had been ineffective were randomized to tacrolimus or placebo treatment. Patients were treated either with tacrolimus or placebo twice-daily for 4 weeks. Severity of ...
| Dikenal sebagai Severe Allergic Conjunctivitis | Tacrolimus Ophthalmic | Objective Signs | Corneal Involvement | Clinical Trial |
TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts
[ PUBLICATION ]
Giant papillary formation containing newly formed vessels is a major characteristic of severe allergic conjunctivitis, such as atopic keratoconjunctivitis (AKC) or vernal keratoconjunctivitis (VKC). We examined production of vascular endothelial growth factor (VEGF) from cultured conjunctival fibroblasts from normal volunteers under stimulation with type 1-, type 2-helper T cell derived and proinflammatory cytokines to investigate the mechanism of giant papillae formation in AKC/VKC. ...
| Dikenal sebagai Conjunctival Fibroblasts | Vascular Endothelial | Growth Factor | Vegf Concentration | Akc Vkc |
KOL-Index: 9650
PURPOSE: To prospectively assess the clinical and visual outcomes of phacoemulsification and implantation of a rollable intraocular lens (IOL) with a thin optic and compare the results with those of implantation of a foldable acrylic IOL.
SETTING: Department of Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Chiba, Japan.
METHODS: Sixteen consecutive eyes of 8 patients (4 women, 4 men) with corticonuclear cataract had small-incision clear corneal ...
| Dikenal sebagai Intraocular Lens | Thinoptx Iol | Phacoemulsification Implantation | Visual Acuity | 6 Months |
Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease
[ PUBLICATION ]
We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. ...
| Dikenal sebagai Ocular Surface | Topical Cyclosporine | Eye Patients | Chronic Graft | Host Disease |
Measurement of IL‐4 in tears of patients with seasonal allergic conjunctivitis and vernal keratoconjunctivitis
[ PUBLICATION ]
To elucidate the mechanism of ocular surface allergic disease, we focused on IL-4, which is one of the key factors in regulating IgE production, and thus determined the concentration of IL-4 in tears. IL-4 concentration was determined in the tears of 15 patients with seasonal allergic conjunctivitis, 15 vernal keratoconjunctivitis (VKC), 10 giant papillary conjunctivitis (GPC), 10 patients with non-allergic conjunctivitis and post-cataract surgical conjunctivitis as intermediate ...
| Dikenal sebagai Allergic Conjunctivitis | Tears Patients | Vkc Gpc | Normal Controls | Linked Immunosorbent |
Orang -orang kunci untuk Allergic Conjunctivitis
Top Kols di dunia
Hiroshi Fujishima:Dampak ahli
Konsep yang manaHiroshi Fujishimamemiliki pengaruh langsung:Allergic conjunctivitis, Dry eye, Atopic keratoconjunctivitis, Conjunctival fibroblasts, Allergic conjunctival disease, Brush cytology, Ocular surface, Vernal keratoconjunctivitis.
Hiroshi Fujishima:Dampak Kol
Konsep yang terkait dengan karya penulis lain yang manafor which Hiroshi Fujishima memiliki pengaruh:Dry eye, Ocular surface, Allergic conjunctivitis, Tear film, Amniotic membrane, Cataract surgery, Contact lens.
Tools
Apakah ini profil Anda? Klaim profil Anda Salin URL Sematkan tautan ke profil Anda |